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Abstract: Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great
potential in the treatment of inflammation-related conditions. Numerous early stage clinical trials
have suggested that this treatment strategy has potential to lead to significant improvements in
clinical outcomes. While promising, there remain substantial regulatory hurdles, safety concerns,
and logistical issues that need to be addressed before cell-based treatments can have widespread
clinical impact. These drawbacks, along with research aimed at elucidating the mechanisms by which
MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as
anti-inflammatory therapeutic agents. The use of MSC-derived EVs for treating inflammation-related
conditions has shown therapeutic potential in both in vitro and small animal studies. This review will
explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory
and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid
arthritis, Alzheimer’s disease, cardiovascular disease, and preeclampsia. Along with this, the mech-
anisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative
tissues will be reviewed, giving insight into their therapeutic potential. Challenges and future per-
spectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will
be discussed.
Keywords: mesenchymal stromal cells; extracellular vesicles; inflammation; regeneration; osteoarthri-
tis; rheumatoid arthritis; Alzheimer’s disease; cardiovascular disease; preeclampsia
1. Introduction
Inflammation is a crucial mechanism initiated by the body as a first line of defence
against harmful stimuli such as pathogens, tissue damage, radiation, and toxic com-
pounds [1]. An acute inflammatory response is normally triggered by immune cells sensing
a pathogen or endogenous stress signal, resulting in the release of pro-inflammatory cy-
tokines and chemokines. This reaction can have a multitude of effects, including neutrophil
and macrophage activation, vasodilation, hypotension, induction of capillary leakage,
and platelet activation [1,2]. These effects typically facilitate tissue regeneration or the
clearance of infection, ultimately leading to the removal of the initial harmful stimuli.
Once cleared of harmful stimuli, the multifaceted process of inflammation resolution
can begin, which involves substantial reprogramming of cells to the anti-inflammatory
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phenotype [2]. Unfortunately, acute inflammation can often progress into chronic non-
resolving inflammation, which may elicit more harm to the body than the initial stimuli
that triggered the inflammatory response [3]. Though not the primary cause, non-resolving
chronic inflammation has been identified to play an important role in the pathogenesis
of a myriad of debilitating diseases including rheumatoid arthritis [2,4], atherosclero-
sis [2,5], Alzheimer’s disease [6], various cancers [2,7–9], asthma [10], type 2 diabetes [11],
diabetic nephropathy [12], osteoarthritis [13–15], multiple sclerosis [16], depression [17],
chronic rhinosinusitis [18], idiopathic pulmonary fibrosis [19], and atrial fibrillation [20].
These diseases share many common pathophysiological mechanisms, including the activa-
tion of inflammatory cells, release of soluble inflammatory factors (most notably cytokines
and chemokines), and extracellular matrix (ECM) remodelling [21].
With such a long list of conditions in which non-resolving inflammation plays a key
role, there is no doubt that it imposes an immense burden on society. Unfortunately,
commonly used anti-inflammatory treatments such as non-steroidal anti-inflammatory
drugs (NSAIDs) and glucocorticoids appear to merely relieve symptoms of the underlying
disease, and there is little evidence to demonstrate that these treatments have any effective-
ness in ceasing disease progression [22]. As such, there is an urgent need to develop new
therapeutic strategies, which perhaps can act on multiple pathways of disease progression
rather than only targeting the inflammatory characteristics.
Mesenchymal stromal cells (MSCs), previously commonly referred to as mesenchy-
mal stem cells [23], are the most widely explored cell type for cell-based therapeutics,
and their use in clinical trials to treat a wide range of diseases has increased dramati-
cally over the past two decades [24]. The literature provides ample evidence of studies
showing the beneficial effects of MSCs when applied for treating inflammatory diseases
in animal models [25,26], with evidence in multiple tissue types including cardiovas-
cular (myocardial infarction, vascular disease, peripheral artery disease, preeclampsia);
neural (multiple sclerosis, Parkinson’s disease, Alzheimer’s disease); and osteochondral
(rheumatoid arthritis, osteoarthritis) [26–29]. As such, there is an ongoing urge within the
scientific community to translate these promising findings to humans. It was initially be-
lieved that the therapeutic potential of MSCs was a function of injected MSCs engrafting to
existing cellular structures, and subsequently differentiating and facilitating the formation
of neo-tissue [30]. However, this belief has been subverted in recent years. It has been
widely observed that implanted MSCs show very low levels of engraftment (less than 3%)
in the target tissue [31], with the vast majority of the population of implanted cells being
rapidly cleared [32]. For this reason, other mechanisms have been investigated, and it is
now evident that the regenerative, anti-inflammatory, and immunomodulatory capacity of
MSCs is exerted through their secretion of paracrine factors [33–35].
The MSC secretome accounts for all molecules secreted by the cell. It includes a variety
of chemokines, cytokines, immunomodulatory factors, and ECM components, along with
a range of other proteins, nucleic acids, and lipids [32]. It is suggested that once MSCs are
implanted into damaged or diseased tissue, they secrete a host of anti-inflammatory and
regenerative factors that elicit a therapeutic response. Importantly, the secretion profile
appears to be a function of the microenvironment around the secreting cell, for instance,
MSCs exposed to inflammatory signals can elicit an enhanced secretory profile [36]. How-
ever, the majority of investigations surrounding this observation have been in vitro gene
expression or proteomic studies and require further in vivo validation [32].
It has been suggested that the apoptosis or phagocytosis of implanted MSCs act as the
trigger for the observed immunomodulatory effects elicited by MSCs [32]. There are so
far two key observations supporting this mechanism. First, observations in mouse models
of graft-versus-host disease have demonstrated that, for MSCs to exert their immunosup-
pressive effects, they must first undergo natural killer cell/T-cell induced apoptosis [37].
Second, observations in a mouse model showed that injected populations of MSCs were
rapidly cleared through monocytic phagocytosis. The monocytes that phagocytosed the
MSCs were shown to modulate their phenotype, which changed the course of the immune
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response [38]. These two observations provide a potential hypothesis for the mechanisms
of MSC-mediated immunomodulation, though further studies are required to confirm
the details.
Aside from the above two proposed mechanisms underlying the therapeutic effects
of MSCs, a third mechanism has gained increasing attention in recent years: extracellular
vesicles (EVs) derived from MSCs. This will be the topic of focus in this review that will be
discussed in the context of treating inflammation-related conditions.
2. The Fundamentals of Extracellular Vesicles
EV is an umbrella definition which encompasses all vesicles released or ’shed’ by
cells [39]. Typically, EVs have a diameter in the range of 30–2000 nm. They consist of a
lipid bi-layer membrane encasing an organelle-free cytosole, which contains a combination
of various proteins, lipids, and nucleic acids [40,41]. EVs have been recently discovered as
a key mechanism of the intercellular communication network. Since EV release was first
observed in rat and sheep reticulocytes in the early 1980s [42,43], an ever-growing number
of cells have been shown to release EVs as a form of intercellular communication. Almost all
mammalian cell types have demonstrated EV secretion including stem cells, neuronal cells,
immune cells, and cancer cells [39,44]. EVs have also been isolated from an extensive range
of biological fluids including blood, urine, semen, breast milk, cerebrospinal fluid, bile,
amniotic fluid, and ascites fluid [44]. Interestingly, EV secretion has been observed in lower
eukaryotes and prokaryotes, with speculations that microbial EVs may mediate the host
response to infection [44,45].
The exact classification of EVs is still evolving, and the current definition of nomen-
clature is not consistently used in the literature [46,47]. Presently, EV classifications are
based on their size and biogenesis [46], with three widely accepted distinct populations.
Exosomes are the most widely studied subpopulation of EVs [48]. Although the size range
of exosomes has not been consolidated in the literature, it is generally accepted that they
have a diameter in the range of 20–150 nm. The biogenesis of exosomes begins with endocy-
tosis, a process of invagination of the plasma membrane to form an endosome. Within the
endocytic pathway, endosomes are classified into three sub-populations: early endosomes,
late endosomes, and recycling endosomes [49]. Early endosomes which are not destined for
secretion, recycling, or degradation become late endosomes. Late endosomal membrane
invagination subsequently forms intraluminal vesicles (ILVs) which contain proteins, lipids,
and nucleic acids. At this point, the late endosome now containing a host of small vesicles is
deemed a multivesicular body (MVB) [40]. The MVB has two possible routes, either fusing
with the lysosome where its contents will be recycled or fusing with the plasma membrane.
The latter releases the ILVs into the extracellular space, where they are now referred to
as exosomes. This process is visualised in Figure 1. The formation of ILVs is believed to
be mainly regulated by two processes. First, the endosomal membrane is enriched for
tetraspanins, specifically CD9 and CD63 [50]. Second, the endosomal sorting complexes
required for transport (ESCRTs) are present during the process of ILV formation. These two
processes regulate the initial inward membrane budding of the late endosome, ILV cargo
sorting, and subsequent ILV formation. Although it is generally accepted that the ESCRT
pathway is the main mechanism governing exosome formation, there exist supplemen-
tary mechanisms of ILV formation such as the syndecan–syntenin–ALIX pathway [40].
Since exosomes arise from endosome membrane invagination, they present common pro-
teins associated with this process across all cell types. These proteins include flotillins,
GTPases and annexins (membrane transport and fusion); integrins (adhesion); ALIX and
the tetraspanins CD9, CD63, CD81, CD82 (MVB formation); and major histocompatibility
complex (MHC) molecules (antigen presentation) [51]. Typically, the lipid composition
of exosomes mirrors that of their parent cell. Exosomes are commonly enriched with
cholesterol, phosphatidylserine, ceramide, and sphingomyelin [52]. Interestingly, the con-
centration of diacyl-glycerol and phosphatidyl-choline appear to be lower in exosomes
than their parent cells [53]. The nucleic acid content of exosomes typically consists of
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mRNAs, microRNAs (miRNAs), and other non-coding RNAs [51], although genomic and
mitochondrial DNA have also been found in exosomes [54,55].
Figure 1. Extracellular vesicle (EV) biogenesis, secretion, and uptake [56]. Exosomes (20–150 nm) are intraluminal vesicles
(ILVs) formed by inward budding of the endosomal membrane during maturation of multivesicular body (MVB), which are
secreted upon fusion of the MVBs with the plasma membrane. Microvesicles (50–1000 nm) are a heterogeneous group of
vesicles with different membranes depending on their origin and morphology. Apoptotic bodies are shedding vesicles
derived from apoptotic cells. After their release into the extracellular space, EVs can bind to cell surface receptors to
initiate intracellular signalling pathways. EVs can also be internalised through processes such as macropinocytosis and
phagocytosis, or by fusion with the plasma membrane. The cargo of EVs consisting of proteins, nucleic acids and lipids are
released in the intracellular space or taken up by the endosomal system of the recipient cell. Reproduced with permission
from [56].
The second most widely studied subpopulation of EVs are microvesicles (MVs) [48].
It is generally accepted that MVs have a diameter in the range of 50–1000 nm, meaning
that they may have a size overlap with exosomes. This creates challenges for purely
size-based EV isolation techniques in distinguishing between exosome and MV popula-
tions [39]. In contrast to exosomes, MVs are formed through direct shedding from the
plasma membrane of the parent cell. The formation of MVs is regulated by aminophospho-
lipid translocases, which control the phospholipid re-distribution in the plasma membrane
and the dynamics of cytoskeletal actin-myosin contractions [57]. As MVs form through
direct outward budding of the plasma membrane (Figure 1), they share many of the same
membrane markers as their parent cell, which may include integrins, selectins, and CD40
ligand [58]. The variations in membrane markers among MVs is a result of the induced
changes which occur during the process of nucleation and budding [51]. The cargo car-
ried by MVs, like exosomes, is not simply representative of the cytoplasmic content.
Some loading mechanisms such as ARF6 trafficking of proteins and CSE1L nucleic acid
export have been identified [59,60]. However, the exact mechanisms of regulation remain
incompletely understood and constitute an area of active research. The protein and nucleic
acid content of MVs are dependent on the cell type along with the external physiologi-
cal conditions experienced by the parent cell [40]. A number of proteins are commonly
identified in MVs, such as matrix metalloproteinases (MMPs), cytoskeletal components,
and glycoproteins [51]. Like exosomes, MVs generally contain a combination of mRNAs,
miRNAs, and other non-coding RNAs [51], as well as possible genomic and mitochondrial
DNA [54,55].
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Apoptotic bodies are the final widely recognised subpopulation of EVs. They are by
far the largest in size, ranging 500–5000 nm in diameter, and are produced by outward
membrane blebbing on the surface of cells undergoing apoptosis [58,61]. There is no
evidence that apoptotic bodies play a role in intercellular communication or have a potential
therapeutic effect, although they do show potential to be used as disease biomarkers [62].
EV-cell communication can occur through several distinct pathways: lysis of EVs in
the extracellular space releasing their contents, direct EV-cell binding, membrane fusion
and release of EV contents, and EV uptake into the endocytic system [56,63]. Ligand-
receptor binding associated with EV extracellular content release and direct EV binding are
believed to be the mechanisms behind several of the biological effects exerted by EVs on
cells, such as growth and angiogenic factor delivery [63]. For the nucleic acids or proteins
suspended in the EV cytosol to act as messengers in the recipient cell, the EVs must fuse
either with the plasma membrane after ligand-receptor binding, or with the endosomal
membrane after endocytosis [63]. Endocytosis of EVs is thought to be the most common
route of uptake [40,41,63], although several questions remain to be answered about this
uptake route. Since the endocytic pathway inevitably ends with degradation or expulsion
from the cell, the cargo carried by the EVs must exit the endosome somehow and find its
way into the cytoplasm if it is to alter cell composition and function [40]. Although this
phenomenon of endosomal escape has been widely observed, the underlying mechanisms
are still unclear [40,64,65]. EV–cell communication is known to be involved in an extensive
range of biological processes, including modulation of the immune system [66,67], neuro-
biological functions such as synaptic plasticity [68], and stem cell differentiation [69,70].
With the extensive role that EVs play in biological processes, it is unsurprising that
they are also heavily involved in the pathogenesis of disease. The most in-depth under-
standing of this concept is in tumour biology [71]. EVs have been shown to have important
roles in promoting tumour cell proliferation [72,73], angiogenesis [73,74], ECM remod-
elling [75], and metastasis [58,75]. Although beyond the scope of this review, there is a
great potential in targeting the phenotype altering mechanisms exerted by EVs in tumour
biology to help develop new treatment strategies, as well as to apply stem cell-derived
EVs as cancer therapeutics [76]. In the field of regenerative medicine, EVs derived from
stem cells are shown to replicate the therapeutic properties of the parent cells, and have
demonstrated many beneficial effects such as apoptosis suppression [77], promotion of
cellular proliferation [78] and angiogenesis [79], and the ability to modulate the diseased
cell phenotype to facilitate tissue regeneration [80]. The precise cargo carried by EVs and
the mechanisms which facilitate their regenerative potential are still unclear. However,
it is known that EV composition is a function of its cellular origin and physiological con-
ditions [81]. By varying factors such as cellular stress, media composition, and physical
stimulation, or by enriching certain miRNAs in the parent cells, it may be possible to
optimise the EV composition for specific regenerative applications [82–85].
Over the past decade, MSC-derived EVs have been increasingly explored in regen-
erative medicine to treat disease or promote repair through local delivery in a range of
tissue types, including cardiovascular, musculoskeletal, neural, renal, hepatic, lung, dermal,
and reproductive tissues [56,86]. It is thought that the MSC-derived EVs can deliver the
same anti-inflammatory and trophic effects as the parent cells [87]. Compared to injecting
live cells into tissues, MSC-derived EVs bypass potential safety concerns of the MSCs
exhibiting uncontrollable behaviour or differentiating into problematic tissue at the site
of injection [88]. The EVs also have an additional advantage of presenting minimal tox-
icity and immunogenicity, even when applied xenogenetically as a large dose at high
frequency [89]. The rest of this review will summarise the current state of research into
MSC-derived EVs as therapeutic agents for treating a number of inflammation-related
conditions: osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, cardiovascular dis-
ease, and preeclampsia (Figure 2). For each of these conditions, evidence related to the
therapeutic effects of MSC-derived EVs has been collected from a range of experimental
studies published within the last ten years, as shown in Table 1. These conditions represent
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examples of diseases with significant societal impact, where pathogenesis is closely linked
with inflammation in musculoskeletal, neural, and cardiovascular tissues as three major
body systems. MSC-derived EVs have also demonstrated beneficial effects in other condi-
tions and body systems impacted by inflammation, such as graft-versus-host disease [90],
kidney disease [91], liver failure [92], and skin wounds [93], although a detailed discussion
of these is beyond the scope of this review.
Figure 2. Summary of the application of mesenchymal stromal cell (MSC)-derived EVs in treating inflammation-related
conditions as covered in this review: osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, cardiovascular disease,
and preeclampsia.
3. Extracellular Vesicles from Mesenchymal Stem Cells for the Treatment of Osteoarthritis
Osteoarthritis (OA) is the most prevalent joint disease globally, affecting 18% of women
and 10% of men over the age of 60 [94]. While OA is generally characterised by the degener-
ation of articular cartilage, it is a disease affecting the entire joint including the subchondral
bone and synovium [95]. Although not the primary defining feature of OA, chronic inflam-
mation forms an important part of the catabolic environment that induces the irreversible
progression of joint degeneration [96]. The exact pathogenesis of OA is incompletely un-
derstood, but it is generally accepted that antagonistic biomechanics acting on a vulnerable
joint is intrinsically linked to disease progression [94]. A number of risk factors including
age, obesity, abnormal joint morphology, and prior joint injury are strongly associated
with the development of OA. Once the disease progresses, the regeneration of damaged
joint structures is unlikely. Non-surgical treatments such as anti-inflammatory medication
and intra-articular injections of corticosteroids or hyaluronic acid may help to relieve pain,
although these have shown little to no benefit in slowing disease progression [97]. With a
lack of viable treatment options, the final destination for most patients after all options
have been exhausted is total joint replacement, which surgically removes the diseased joint.
Although this can lead to significant pain reduction and overall improved quality of life,
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the level of activity post-surgery is relatively low compared to pre-replacement levels due
to component failure or loosening [98], and the implant may need revision in younger
patients due to having a limited lifetime of approximately 20 years [99].
The use of MSCs to treat OA has shown promise over the last decade, with numerous
early clinical studies suggesting that this approach is safe and effective, and may lead to
significant improvements in clinical outcomes along with some preservation or regenera-
tion of damaged joint tissues [100,101]. However, there remain significant hurdles before
MSCs can be scaled up for widespread clinical use, due to limited cell survival following
injection, inability to be used as an ‘off-the-shelf’ therapy, and regulatory issues associated
with the injection of live cells [102]. The use of MSC-derived EVs circumvents these issues,
and have shown promising preliminary outcomes in both in vitro and small animal models
of OA, as described below and in recent reviews on this topic [87,103].
The 16 studies on OA described in Table 1 demonstrate relatively consistent thera-
peutic effects of MSC-derived EVs. The MSCs used to generate EVs were derived from
many different sources, including bone marrow [83,104–107], adipose tissue [82,85,108,109],
synovial membrane [84,110], embryonic stem cells [111–113], and induced pluripotent stem
cells [110,114]. The majority of studies used exosomes [83–85,105,106,110–115], while others
used MVs [107] or a heterogenous population of EVs that likely contained both exosomes
and MVs [82,108,109]. One study also compared the effects of exosomes and MVs [104].
There was not a consensus among the studies on the methods of identifying EV popu-
lations, with some purely based on size and others based on size and protein markers,
although the size and exact protein markers were also not consistent. The terminology
used to refer to EV populations varied among studies, with MVs and microparticles being
used interchangeably.
The in vitro experiments conducted using MSC-derived EVs in OA cell models showed
that the EVs were quickly internalised by the treated cells, usually within 30 min [82,84,106,107].
It was also widely observed that EVs improved the migration and proliferation potential
of the treated cells [83,84,110,113–115], together with increased viability and reduced
rate of apoptosis, and that the improvements were dose-dependent [85,104,107,113–115].
EV treatment of OA chondrocytes and fibroblasts commonly resulted in the upregulation
of anabolic proteins such as aggrecan, and collagen types I and II [85,104,106,109,111].
This was accompanied by the downregulation of catabolic markers such as MMP-13 and
ADAMTS5 [83,85,109,115]. EV treatment also showed anti-immunomodulatory and anti-
inflammatory effects, through the suppression of COX-2, IL-1α, IL-1β, IL-6, IL-8, IL-17,
and TNF-α [106,109], as well as the inhibition of macrophage activation [113].
Among the 15 studies that performed in vivo investigations, six were performed in
rats [84,105,109,112,113,115], seven in mice [82,83,85,104,109–111], and two in rabbits [107,114].
The method of inducing OA differed among studies: injection of monosodium iodoacetate
(MIA) [109] or collagenase [83,104,110,115]), surgical destabilisation of the medial meniscus
(DMM) [85,109,111] or medical collateral ligament and medial meniscus transection [84],
induction of osteochondral defects [107,112–114], and muscular injury through cardiotoxin
injection [82]. All studies demonstrated a positive therapeutic effect exerted following
EV administration.
In MIA and collagenase-induced OA models, all studies showed that EVs could atten-
uate OA progression to varying degrees [83–85,105,109–111,115], with some studies demon-
strating the regeneration of osteochondral tissue [83,84,104,105,110,115]. Many reported
a suppression of catabolic markers (MMP-13, ADAMTS5) [85,105,109] and an increase
in anabolic markers (collagen type II, proteoglycan, aggrecan) [85,105,111]. Other re-
ported effects of EVs included significant analgesia [105], subchondral bone regenera-
tion [105], and reduced synovial inflammation [109]. EVs enriched with specific miRNAs
(IncRNA KLF3- AS1, miR92a-3p, miR-140-5p, miR1005p) were shown to produce improved
therapeutic outcomes [83–85,115].
Similarly, in surgically induced OA models, all studies showed that EVs could atten-
uate OA progression [84,85,109,111], together with downregulation of catabolic markers
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(MMP-13, ADAMTS5) and upregulation of anabolic markers (collagen type II) [85,109,111].
The enrichment of EVs with miR-140-5p significantly improved the level of osteochondral
protection from OA progression [84], and gait abnormalities in the DMM model were
found to be alleviated following exosomes treatment [85].
In studies using an osteochondral defect model, EV treatment resulted in complete
neo-tissue infilling and the development of hyaline-like cartilage that was integrated with
the surrounding tissue [107,112–114]. An increase in PCNA-presenting cells and decrease
in CCP3 apoptotic cells was also observed, along with the switching of macrophage
phenotype from M1 (pro inflammatory) to M2 (anti-inflammatory) and suppression of
inflammatory cytokines [113]. In the study that used a cardiotoxin-induced muscular
injury model, EVs were shown to accelerate muscular regeneration, and have an anti-
inflammatory function that increased M2 anti-inflammatory markers and reduced M1
inflammatory markers [82].
4. Extracellular Vesicles from Mesenchymal Stem Cells for the Treatment of
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is the second most common form of arthritis, after OA.
There is no cure for RA, with the only treatments being physical therapy and medication to
help relieve symptoms and slow disease progression. RA is an autoimmune disease that
is primarily defined by chronic joint inflammation, together with bone erosion and ECM
destruction [116]. The pathogenesis of RA is driven by pre-existing genetic disposition
coupled with risk factors that increase the likelihood of disease progression, such as
smoking, silica dust exposure, vitamin D deficiency, and obesity [117]. The transition to
a chronically inflamed synovium in RA is incompletely understood, although it may be
triggered by a number of antagonistic stimuli such as local microtrauma, microvascular
injury, and complement activation. Additionally, autoantibodies can activate periarticular
osteoclasts, a step which initiates bone damage and is associated with the release of
TNF-α and IL-8, both of which promote synovitis [118]. Once synovitis is established,
the synovial ECM is disrupted, and there is activation of stromal cells together with a
myriad of infiltrating cells including T-cells, B-cells, macrophages, mast cells, and plasma
cells. Disease progression involves a complex and incompletely understood relationship
between cells and soluble immune factors, most notably chemokines and cytokines [4].
Driven by the well-known anti-inflammatory and immunomodulatory functions of
MSCs, a handful of studies have explored the use of MSC-derived EVs as a therapeutic for
RA. In contrast to the number of publications available for OA, there were only five studies
that applied MSC-derived EVs to experimental models of RA or inflammatory arthritis,
as shown in Table 1. Of these, four studies sourced MSCs from the bone marrow [119–122],
and one from RA synovial fluid and human neutrophils [123]. All studies applied exo-
somes as the EV subpopulation of interest, including one that used both exosomes and
MVs [123]. The exosomes used in most studies were characterised to be approximately
100 nm in diameter [119,121,122], while the diameter of MVs was within the range of
150–575 nm [120].
For the in vitro experiments, two studies implemented a RA cell model comprising
fibroblast-like synoviocytes (FLS) isolated from the diseased tissue of RA patients [119,121].
The invasion of RA FLS into cartilage and angiogenesis are important processes mediating
the pathogenesis of RA. Both studies explored the enrichment of exosomes with a spe-
cific miRNA, namely miR-150-5p [119] or miR-124a [121]. Both studies showed that the
miRNA-enriched exosomes could inhibit the increased migration and invasion associated
with RA FLS. In one study, a co-culture of RA FLS with human umbilical vein endothe-
lial cells (HUVECs) that was treated with miR-150-5p-enriched exosomes substantially
inhibited tube formation, compared to exosomes that were enriched with a control miRNA
(miR-67) [119], suggesting that the former could suppress angiogenesis. When treated
with inflammatory cytokines, RA FLS were shown to upregulate MMP-14 and vascular
endothelial growth factor (VEGF), but this upregulation was attenuated when the cells
were treated with miR-150-5p-enriched exosomes [119]. These findings led to the hypothe-
Int. J. Mol. Sci. 2021, 22, 3023 9 of 34
sis that miR-150-5p delivered by exosomes could be one of the mechanisms responsible
for suppressing cell migration, invasion, and tube formation in RA. In the other study,
the effects of miR-124a-enriched exosomes on RA FLS were compared with unaltered exo-
somes by evaluating proliferation, cell cycle progression, apoptosis, and ‘wound’ closure
(modelled by a wound scratch assay) [121]. The miR-124a-enriched exosomes were found
to induce a more pronounced suppression of proliferation, arrest of the cell cycle in the
G0/G1 phase rather than the S phase, stronger inhibition of the wound closure healing rate,
and similar levels of apoptosis in RA FLS compared to unaltered exosomes [121]. One other
study involving an in vitro investigation explored the immunomodulatory effects of exo-
somes and MVs derived from both IFN-γ-primed and un-primed murine bone marrow
MSCs on murine T- and B-lymphocytes [120]. Both primed and un-primed MSC culture
media were found to suppress the proliferation of T-lymphocytes. After centrifugation,
the culture medium supernatant lost its ability to suppress proliferation, suggesting that
the immunomodulatory agents secreted by MSCs were present in the EV-containing pellet.
The EVs were shown to have dose-dependent effects on suppressing T-lymphocyte prolifer-
ation, but these suppressive effects were lost when the EVs were subjected to a freeze-thaw
cycle. Both exosomes and MVs were shown to have the ability to suppress several types of
pro-inflammatory cells (CD8+ IFN-γ+ and CD4+ IFN- γ+ cells) and increase the number of
anti-inflammatory cells (CD4+ IL-10+ Tr1 and CD4+ CD25+ Treg).
Three studies performed in vivo experiments using a collagen-induced arthritis (CIA)
model in mice or rats. Two explored the enrichment of exosomes with specific miRNAs,
miR-150-5p [119] or miR-192-5p [122]. The third used exosomes and MVs derived from IFN-
γ-primed and un-primed murine bone marrow MSCs [120]. Treating CIA mice with miR-
150-5p-enriched exosomes resulted in reduced levels of inflammation, as measured by hind
paw thickness and reduced clinical arthritis scores compared to PBS and exosomes enriched
with a control miRNA (miR-67) [119]. Mice treated with miR-150-5p-enriched exosomes
also showed downregulation of VEGF (angiogenic factor), CD31 (angiogenesis marker),
and MMP-14 (promotes the characteristic invasion of FLS into cartilage). When miR-192-
5p-enriched exosomes were injected into CIA rats, they were found to migrate from the
bloodstream into synovial tissue, where they downregulated the expression of a number of
factors that normally show upregulation in the CIA model (RAC2, TRAP, PGE2, IL-1β, TNF-
α, NO, and iNOS) and upregulated miR-192-5p expression [122]. To identify an optimal
dose of EVs for the CIA model, a study comparing exosomes and MVs first employed
a delayed type hypersensitivity (DTH) model to measure inflammation through paw
swelling [120]. Both exosomes and MVs exerted a dose-dependent anti-inflammatory effect
and were the most effective at the maximum dose of 250 ng. Carrying this dose into the
CIA model, the exosomes-treated group developed arthritis at a rate of 5% with extremely
low clinical arthritis scores, compared to the MVs-treated group at 20% and higher clinical
arthritis scores. Both EV groups performed significantly better than the PBS-treated group,
which developed arthritis at a rate of 47% with relatively severe clinical arthritis scores.
In a separate experiment using the CIA model, a 250-ng dose of exosomes was shown
to have a superior anti-inflammatory effect compared to 500 ng of MVs, as assessed
through paw swelling, lower rates of arthritis development, and lower clinical arthritis
scores [120]. In addition, one study used both K/BxN- and glucose-6-phosphate isomerase
(GPI)-induced inflammatory arthritis models [123]. Treatment with a neutrophil-derived
EV population that likely contained both exosomes and MVs was found to reduce cartilage
degradation and proteoglycan loss, and this chondroprotective effect was shown to require
AnxA1. The interactions of AnxA1 in MVs with the FPR2/ALX receptor was suggested to
increase TGF-β production by chondrocytes.
5. Extracellular Vesicles from Mesenchymal Stem Cells for the Treatment of
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, characterised by a
progressive and irreversible degeneration of the central nervous system (CNS). The patho-
logical hallmarks of AD include extracellular amyloid-β plaques, neurofibrillary tangles,
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and neuronal dysfunction and degeneration [124]. Chronic neuroinflammation is now
broadly understood to play an important role in the pathogenesis of AD, which involves
activated microglia and the release of numerous cytokines to produce a sustained immune
response [125]. Due to its complex pathophysiology, there are currently no effective treat-
ments for AD. The only approved drugs used for AD treatment provide only symptomatic
relief rather than slowing the progression of disease.
Due to their anti-inflammatory, pro-regenerative, and immunomodulatory character-
istics, MSCs have been recently considered as a possible treatment for AD [126]. However,
despite the promising trophic functions of these cells demonstrated in preclinical models of
AD, there are concerns surrounding their intracranial transplantation in a clinical setting,
which is associated with increased risks of complications and mortality [126]. In this context,
the use of MSC-derived EVs may provide a breakthrough strategy for the treatment of AD,
that can convey the therapeutic effects of the parent cells while exhibiting the advantages of
small size, low immunogenicity, and lack of ability to undergo malignant transformation.
As shown in Table 1, the 11 studies on AD demonstrated a range of therapeutic
effects elicited by MSC-derived EVs in both in vitro and in vivo experimental models.
The MSCs were derived from various sources, including bone marrow [127–131], adi-
pose tissue [132], umbilical cord [133,134], Wharton’s Jelly [135], and commercially ob-
tained MSCs with an unspecified origin [136]. One study also used neural stem cells
(NSCs) isolated from the hippocampus of mice as the cell source [137]. Half of the studies
used a heterogeneous population of EVs [128–130,132,135], while the other half used exo-
somes [127,131,133,134,136,137]. Different size ranges and protein markers were used to
identify EV populations in these studies.
Six of the studies involved in vitro experiments, four of which used amyloid-β
oligomers (AβO) to induce disease, since this has been identified as the major toxic species
driving neuroinflammation in AD. Two studies used hippocampal cells [128,135], one used
primary cortex neurons [132], and one used microglia [133] as AβO-induced AD models.
The other two studies used an AD model comprising microglia exposed to inflammatory
cytokines (TNF-α and IFN-γ) [130], or neuroblastoma cells transfected with amyloid pre-
cursor protein (APP) gene to overexpress Aβ peptides [134]. In the two studies that used
hippocampal cells, one used neurons exclusively [128], while the other used a mixture of
hippocampal cells including neurons and astrocytes, as well as a neuron-only oxidative
stress model [135]. The hippocampal cells treated with AβO showed a much higher level
of EV uptake than control cells, although it was also noted that the uptake of EVs was
primarily performed by astrocytes rather than the neuronal cells [135]. The EVs were
shown to have an anti-oxidant effect, as they protected against synapse damage [128] and
prevented the formation of reactive oxygen species (ROS) in hippocampal cells induced
by AβO [135]. However, once the catalase (a known anti-oxidant) content of EVs was
inactivated, these protective effects of EVs were lost [128,135]. In the two studies that used
microglia, one showed that, after AβO treatment, the application of exosomes increased
the markers for alternative activation into the anti-inflammatory M2 microglia phenotype,
as well as induced higher levels of anti-inflammatory cytokines (IL-10 and TGF-β) and
lower levels of pro-inflammatory cytokines (IL-1β and TNF-α) [133]. The other study
showed that, after microglial pre-treatment with inflammatory cytokines, the application
of EVs significantly reduced the production of the pro-inflammatory cytokines IL-6 and
IL-1β and increased the production of the anti-inflammatory cytokine IL-10 [130]. In the
remaining AD cell models, the EVs were shown to reverse neuronal toxicity [132] and
reduce the levels of secreted and intracellular Aβ [134].
From the nine studies that performed in vivo investigations, eight used transgenic
mice pre-determined to develop an early onset of AD [127,129–134,137], and one used
an amyloid-β aggregate-induced AD mouse model [136]. Treatment with EVs led to a
range of beneficial effects, including reduced plaque deposition in both the cortex and
hippocampus [127,129,131]; reduced levels of soluble and insoluble amyloid-β aggre-
gates [127,129,132–134]; improved memory and spatial learning abilities as assessed by the
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Morris water maze (MWM) test [127,131,133,134,136,137]; improved memory as assessed
by the Novel Object Recognition (NOR) test [132,136]; reduced levels of pro-inflammatory
markers (including IL-6, IL-β, IL-α, IL-1β, and TNF-α) [127,133,137]; increased levels
of anti-inflammatory markers (including IL-13, IL-10, IL-4, and TGF-β) [127,133]; in-
creased levels of the AβO degrading enzymes neprilysin (NEP) [131,133] and insulin-
degrading enzyme (IDE) [133]; reduced numbers of pro-inflammatory M1 microglia [130,133];
and increased numbers of anti-inflammatory M2 microglia [133]. One study explored the
conjugation of EVs with the rabies virus glycoprotein (RVG) to improve targeting of the
nerve tissue [127]. Compared to unconjugated EVs, conjugated EVs showed increased
migration from the bloodstream into the cortex and hippocampus. This resulted in lower
plaque deposition in these brain regions, as well as greater reduction in AβO aggregates, in-
creased levels of anti-inflammatory markers, decreased levels of pro-inflammatory markers,
and improved spatial learning and memory ability as assessed by MWM. Another interest-
ing study cultured MSCs on graphene 2D films or 3D scaffolds and compared the effects of
the resulting exosomes [134]. The 3D exosomes were found to be much more effective at
improving spatial learning and memory, reducing Aβ deposition, and reducing neuroin-
flammation and oxidative stress in AD mice compared to 2D exosomes. These differences
were thought to be related to the topographical structures of the 3D scaffold, which might
have led to increased secretion of protective factors by the parent MSCs that were then
captured in the exosomes.
6. Extracellular Vesicles from Mesenchymal Stem Cells for the Treatment of Cardio
Vascular Disease
Acute myocardial infarction (AMI) is the leading cause of death in people with car-
diovascular disease worldwide. AMI is characterised by insufficient blood supply to the
heart leading to cardiac ischemia, decrease in functioning cardiomyocytes, and death of
myocardial tissue [29,138]. The irreversible progression of cardiomyocyte and myocar-
dial tissue necrosis negatively impact cardiac function and can result in congestive heart
failure [29,138]. Following AMI, inflammatory cells including macrophages, monocytes,
and neutrophils migrate to the infarcted myocardium to induce repair. However, the
resulting inflammatory response may persist for longer than necessary and lead to further
cardiac damage [139]. MSCs can potentially protect the myocardium following AMI by
suppressing persistent inflammation, stimulating angiogenesis and the differentiation
of fibroblasts within the infarcted region, abrogating apoptosis, and alleviating fibrosis,
hence repairing the myocardium and likely preventing further cardiac dysfunction or heart
failure [138].
Due to the anti-inflammatory, pro-angiogenic and anti-oxidant effects of MSCs, MSC-
derived EVs have been recently investigated for their reparative role in cardiovascular
disease [140,141]. The immunomodulatory role of MSC-derived exosomes was shown in
an in vitro study that used MSCs from healthy human donor bone marrow [140]. The exo-
somes exhibited prominent anti-inflammatory properties on peripheral blood mononuclear
cells (PBMCs), where they attenuated the pro-inflammatory factor TNF-α and elevated
the anti-inflammatory factor TGF-β during in vitro culture. At the later stages of tissue
repair, TGF-β is also pro-fibrotic with a well-established role in cardiac fibrosis, cardiomy-
ocyte apoptosis, and cardiac hypertrophy through activin receptor-like kinase activity
(ALK) [142]. The physiological process of cardiac repair post AMI consists of three ma-
jor stages: inflammatory, proliferative, and maturation. Fibroblasts are the key ‘repara-
tive’ cardiac cells during the inflammatory stage, which are capable of degrading ECM
components and releasing inflammatory mediators (IL-1β, TNF-α) to enhance the in-
flammatory response during cardiac rupture [138]. In contrast, myofibroblasts exhibit
an anti-inflammatory phenotype important for the maturation stage of cardiac repair by
secreting ECM components and anti-inflammatory factors (TGF-β), and enhancing the
differentiation of fibroblasts into myofibroblasts [138].
As seen in Table 1, the 14 included studies all showed therapeutic effects of MSC-
derived EVs in various small animal models of cardiovascular disease. Exosomes from
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several MSC sources including bone marrow, adipose tissue, and umbilical cord were all
shown to have effects in increasing angiogenesis and cardiac function in a left anterior
descending (LAD) coronary artery ligation myocardial infarction (MI) rat model [29].
Related to the process of cardiac repair following AMI as described above, a study showed
that exosomes derived from human umbilical cord MSCs can attenuate the inflammation
induced by cardiac fibroblasts in vitro, and also have cardioprotective effects in vivo in a
lipopolysaccharide (LPS)-induced rat model of MI [138]. These findings were supported
by a similar study where PBS, MSCs, and MSC-derived exosomes were injected into
the peri-infarct zone of rat infarcted myocardium, where the treatment group receiving
exosomes showed the most prominent decrease in the infiltration of CD68+ inflammatory
cells [141]. The MSC-derived exosomes were shown to exert their beneficial effects through
different mechanisms compared to the parent MSCs. In an LAD coronary artery ligation
MI rat model, MSCs and MSC-derived exosomes showed notable distinctions in the
expression of several miRNAs [141]. For example, the expression levels of miR-21 and
miR-15 were significantly lower in exosomes compared to in MSCs. The downregulation
of these miRNAs in exosomes might act to suppress hypertrophy and reduce cardiac
ischaemic injury, which might explain their greater therapeutic benefits compared to
MSCs. Other mechanisms by which MSC-derived exosomes may reduce cardiomyocyte
apoptosis in MI is by regulating cell autophagy through AMPK/mTOR and Akt/mTOR
signalling [143].
Dilated cardiomyopathy (DCM) and inflammatory cardiomyopathy (ICM) are some
of the most multifaceted complications of myocardial inflammation, characterised by ven-
tricular enlargement and subsequent systolic dysfunction [144]. In a doxorubicin-induced
model of dilated cardiomyopathy, cardiac dilation was ameliorated by MSC-derived exo-
somes, which also showed anti-inflammatory effects that decreased the expression of IL-1,
IL-6, and TNF-α cytokines. In addition, these exosomes suppressed the pro-inflammatory
macrophages (ILY6Chigh and M1-like F4/80+ CD11c+) and elevated anti-inflammatory
macrophages (LY6Clow and M2-like F4/80+ CD206+) in the blood and heart of the treated
mice, which restored macrophage polarisation through activation of the JAK2-STAT6 path-
way [144]. Similar effects were demonstrated in a clodronate liposome-induced myocardial
ischaemia-reperfusion (I/R) injury model, where MSC-derived exosomes were capable of
preserving cardioprotective efficacy, reducing inflammation of heart tissue, and inducting
macrophage polarisation by shuttling the miR-182 gene to downregulate inflammatory
toll like receptor 4 (TLR 4) and upregulate the pro-survival PI3k/Akt signalling path-
way [145]. The immunomodulatory effects of MSC-derived exosomes were demonstrated
by reduced M1 gene expression markers (iNOS, IL-1β, IL-6, TNF-α) and increased M2
gene expression markers (Arg1, IL-10, CD206, TGF-β) both in vitro and in vivo [145]. In a
D-galactose aging-induced cardiac dysfunction model, exosomes derived from umbilical
cord MSCs were shown to inhibit cardiac inflammation by increasing the expression of
the long noncoding RNA (lncRNA) MALAT1, which suppressed NF-kB/TNF-α signalling
pathways [146]. Rat bone marrow MSC-derived exosomes carrying miRNA-125b exhibited
substantial therapeutic effects on a myocardial I/R injury rat model, leading to a reduction
in inflammatory factors (IL-β, IL-6, and TNF-α) by downregulating the SIRT7 gene and
thus improving heart function [147]. The miRNA-125b abrogated the infarct area and pro-
vided protection from myocardial ischemia reperfusion injury [147]. The exosomes derived
from LPS-primed bone marrow-derived MSCs showed a potential role in macrophage
polarisation and tissue repair in several inflammatory models [148].
In a mouse MI model, exosomes from bone marrow-derived MSCs, both primed or un-
primed with LPS, were shown to reduce inflammation and myocardial injury by strongly
attenuating LPS-dependent NF-κB signalling and activating the Akt1/Akt2 pathway [149].
The LPS-primed MSC-derived exosomes were found to have the greatest effects on cardiac
inflammation, cell viability, and apoptosis. In rat cardiomyocytes and rats treated with
doxorubicin and trastuzumab to induce oxidative stress, exosomes derived from human
mesenchymal progenitor cells obtained from right cardiac appendage tissue were found
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to reduce cell death, and provide protection against cardiac dysfunction and myocardial
fibrosis [150]. These exosomes were shown to be enriched in miR-146a-5p, which might
act to suppress a number of target genes that encode signalling mediators of inflammation
and cell death in cardiomyocytes.
To increase the efficacy of MSC-derived EVs, drug delivery systems have been devel-
oped to enable their intramyocardial delivery post-AMI. One approach is to encapsulate the
EVs within a self-assembling peptide (SAP) hydrogel modified with a SDKP pattern [151].
The MSC-derived EVs were administered by intramyocardial injection in a rat MI model,
either alone or in conjugation with an angiogenic and anti-inflammatory SAP hydrogel
based on (RADA)4-SDKP [151]. This was found to increase α-smooth muscle actin (SMA)
vessel-like structures to promote angiogenesis, as well as reduced inflammation and pro-
inflammatory CD68+ cells, which resulted in improved ventricular remodelling and cardiac
function. Similarly, exosomes encapsulated in a functional peptide hydrogel could be re-
leased in a prolonged and stable manner in a rat model of MI, resulting in reduced cardiac
damage and improved angiogenesis [152]. In another study, lentivirus packaging was
used to engineer exosomal-enriched membrane protein (Lamp2b) fused with ischemic
myocardium-targeting peptide CSTSMLKAC (IMTP) [153]. The IMTP-exosomes produced
by transfected MSCs were shown to induce a greater reduction in mRNA levels of pro-
inflammatory factors (TNF-α, IL-6, and IL-1β) within the ischaemic heart area in an AMI
model compared to blank exosomes. The group treated with IMTP-exosomes also showed
a reduced percentage of M1 macrophages (TNF-α+ CD68+) and increased percentage
of M2 macrophages (CD206+) compared to groups treated with blank exosomes or PBS.
Furthermore, the IMTP-exosomes were found to reduce cardiac cell apoptosis and infarct
size, and improve vasculogenesis. In an interesting study that combined the delivery
of exosomes and MSCs in a rat MI model, MSC-derived exosomes were given through
intramyocardial injection, with or without intravenous infusion of atorvastatin-pretreated
MSCs on days 1, 3, or 7 after MI [154]. The combined treatment of exosomes followed by
MSC transplantation was found to improve cardiac function, reduce infarct size, and in-
crease neovascularisation to a greater extent than controls treated with exosomes or MSCs
alone. Furthermore, the highest improvement in heart function was achieved by the group
that received exosomes followed by MSCs at day 3 after MI. The delivery of exosomes
before MSC transplantation was found to enhance cell survival and reduce cell apoptosis.
7. Extracellular Vesicles from Mesenchymal Stem Cells for the Treatment of Preeclampsia
Preeclampsia is a life-threatening cardiovascular disorder occurring in the second-half
of pregnancy with multifactorial pathogenesis [155,156]. Although a leading cause of mater-
nal and neonatal morbidity and mortality, there are no current treatments for preeclampsia.
The exact pathogenic mechanisms of preeclampsia are not well understood, but two pheno-
types have been identified based on the time of diagnosis: early-onset (before 34 weeks of
gestation) and late-onset (from 34 weeks of gestation) [155,156]. Early onset preeclampsia
is often associated with inappropriate placentation due to inadequate trophoblast invasion
leading to placental hypoxia. Late-onset preeclampsia is characterised by irregular growth
of the placenta and underlying maternal cardiovascular, metabolic, and inflammatory
conditions [156–158]. Nevertheless, both phenotypes display inflammation, which is of-
ten mediated by abnormally upregulated immune responses and activation of the innate
immune system and pro-inflammatory factors [158]. Imbalance between ROS and anti-
oxidants due to placental hypoxia can also lead to systemic inflammation and endothelial
dysfunction before preeclampsia is manifested. The pathogenic mechanisms underlying
these processes appear to involve the secretion of syncytiotrophoblast macrovesicles, in-
flammatory factors such as TNF-α, and anti-angiogenic factors such as soluble fms-like
tyrosine kinase (sFlt-1) and Endoglin (sEng) into the maternal circulation [156].
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Table 1. Current evidence of the therapeutic effects of EVs in a range of inflammation-related conditions.
OSTEOARTHRITIS
Study Source of EVs Type of EVs Administration and Dose Model(s) Used Major Findings
Cosenza et al., 2017 [104] Mouse bone marrow-derived MSCs Exosomes (112 ± 6.6 nm) and MVs (223 ± 14.5 nm)
In vitro:
Exosomes and MVs were applied to cells at 12.5 ng,
125 ng, or 1.25 µg
In vivo:
Intra-articular injection of 2.5 × 105 MSCs, 500 ng
MVs or 250 ng exosomes in 5 µL saline, at seven
days after OA induction
In vitro:
Mouse chondrocytes treated with IL-1β (1 ng/mL)
In vivo:
Collagenase-induced mouse model of OA; analysis
at 42 days after OA induction
In vitro:
- Exosomes and MVs enhanced anabolic marker expression and decreased
catabolic marker expression; at high doses, the effects of EVs on cells were
similar to those treated with MSCs
- Inhibited macrophage activation
In vivo:
- Exosomes and MVs both showed chondroprotective effects, presenting
with healthy articular cartilage that had no discernible difference compared
to healthy controls at 42 days
- Improved subchondral bone quality and partially prevented ligament and
meniscus calcification
Li et al., 2020 [105] Mouse bone marrow-derived MSCs Exosomes (120.31 ± 15.28 nm)
EVs (200 µg exosomes in 200 µL PBS) were injected
weekly immediately after surgery for four weeks
through the tail vein of mice
In vivo:
Lumbar facet joint resection-induced mouse model
of OA
- EVs had a powerful analgesic effect
- Attenuated cartilage degeneration
- Induced higher proteoglycan levels, and downregulation of MMP-13
and ACAN
- Caused regeneration of osteochondral tissue, as well as maintenance and
regeneration of subchondral bone
- Blocked angiogenesis and aberrant nerve invasion
Liu et al., 2018 [115] Human MSCs (from ATCC) Exosomes (100 nm)
In vitro:
Cells treated with 1, 5, or 10 µg/mL exosomes for
24 h
In vivo:
Intra-articular injection of exosomes from untreated
MSCs and MSCs with knockdown of the lncRNA
KLF3-AS1, at 21 days after OA induction
In vitro:
Rat chondrocytes treated with IL-1β
In vivo:
Collagenase-induced rat model of OA; analysis at
eight weeks
In vitro:
- Partially reversed the changes induced by IL-1β treatment of cells,
including reduced expression of COL2A1 and aggrecan, increased
expression of MMP-13 and RUNX2, reduced migration and proliferation,
and increased apoptosis
In vivo:
- Partially reversed cartilage degradation and expression of
OA-indicative genes
- Exosomes with lncRNA KLF3-AS1 knockdown had the opposite effect,
suggesting that exosomal KLF3-AS1 could promote cartilage repair and
chondrocyte proliferation
Liu et al., 2017 [114] Human iPSC-derived MSCs Exosomes (50–150 nm)
Exosomes were integrated into a hydrogel in a
20 µL volume at 1 × 1011 particles/mL, or given by
intra-articular injection directly in the same volume
and concentration
In vitro:
Human chondrocytes or bone
marrow-derived MSCs
In vivo:
Full-thickness osteochondral defects (4 mm
diameter, 3 mm depth) in rabbits
In vitro:
- Increased the migration of chondrocytes and MSCs
- When cells were hydrogel encapsulated, exposure to exosomes improved
their viability
In vivo:
- Exosomes suspended in the hydrogel formed in situ and integrated well
with surrounding cartilage
- 7 days after implantation, treated joints showed superior cell infiltration
including chondrocytes, inflammatory cells, fibroblasts, and blood cells
- 12 weeks after implantation, treated joints showed complete defect filling
with smooth hyaline-like cartilage (high levels of organised collagen type II
and low levels of collagen type I), and complete integration with
native tissue
Lo Sicco et al., 2017 [82]
Human adipose-derived MSCs cultured in
normoxic (20% O2) or hypoxic (1%
O2) atmosphere
Mostly exosomes but also contained MVs (4–250 nm)
Intramuscular injection of 1 µg EVs in 20 µL PBS,
injected 2 h after muscular injury and repeated after
four days in muscular injury model
In vitro:
Mouse bone marrow-derived macrophages
In vivo:
Mouse cardiotoxin-induced muscular injury model
(analysis at 1, 2, and 7 days after injury)
In vitro:
- MSCs cultured in normoxic or hypoxic conditions produced EVs with the
same size and morphology
- Both EV groups increased the expression of angiogenic molecules and
induced epithelial tube formation, with hypoxic EVs being more angiogenic
- Both EV groups were internalised by macrophages and increased
macrophage proliferation; both demonstrated anti-inflammatory properties
and ability to switch macrophages from M1 to M2 phenotype; hypoxic EVs
had greater effects
- Hypoxic EVs showed downregulation of 48 miRNAs and upregulation of
20 miRNAs; 4 of the upregulated miRNAs were associated with
inflammatory processes (miR-223, miR-146b), proliferation and
differentiation (miR-126, miR-199a)
In vivo:
- Both EV groups showed anti-inflammatory properties, with increase in M2
anti-inflammatory markers and decrease in M1 pro-inflammatory markers
- Both EV groups showed accelerated regeneration of muscle tissue,
although hypoxic EVs had a greater effect
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Mao et al., 2018 [83] Human bone marrow-derived MSCs Exosomes (50–150 nm)
Intra-articular injection of exosomes from untreated
MSCs and MSCs overexpressing miR-92a-3p; 15 µL
at 500 µg/mL injected at 7, 14, and 21 days after
OA induction
In vitro:
Human chondrocytes treated with IL-1β and
human MSCs undergoing chondrogenesis
In vivo:
Collagenase-induced rat model of OA; analysis at
28 days
In vitro:
- Enhanced chondrocyte proliferation and migration
- Upregulated COL2A1, SOX9 and aggrecan, and downregulated MMP-13,
WNT5A, COL10A1 and RUNX2 in MSCs undergoing chondrogenesis
In vivo:
- Exosomes overexpressing miR-92a-3p reversed the OA-related changes
(reduced COL2A1 and aggrecan in the cartilage matrix) to levels slightly
below normal cartilage tissue, suggesting that they can reverse cartilage
degradation in OA
Ragni et al., 2019 [108] Human adipose-derived MSCs Not specified; both small and large EVs
EVs were added to cells at a ratio of 100,000:1
(EVs:cell) for 10 days, with EVs freshly
supplemented every two days
In vitro: Inflammatory OA cell model, comprising
human FLSs isolated from OA patients and
stimulated with IL-1β at physiological levels
(25 pg/mL)
- Downregulated HAS3, MMP1, MMP13, CCL2 and CCL5 gene expression,
and significantly (50%) downregulated CXCL8 expression from 2 to 10 days
- EVs showed clear anti-inflammatory properties, possibly mediated by
direct interaction with hyaluronan matrix and miRNA release
Tao et al., 2017 [84] Human synovial membrane-derived MSCs Exosomes (30–150 nm)
Intra-articular injection of exosomes from untreated
MSCs and MSCs overexpressing miR-140-5p; 100
µL at 1 × 1011 particles/mL injected weekly from




Rat OA model induced through medial collateral
ligament and medial meniscus transection; analysis
at 12 weeks
In vitro:
- Exosomes with normal miR-140-5p content increased chondrocyte
proliferation and migration, but decreased ECM secretion levels
- Exosomes with upregulated miR-140-5p increased chondrocyte
proliferation and migration while maintaining ECM secretion levels
In vivo:
- Exosome with normal miR-140-5p content were mildly chondroprotective
- Exosomes with upregulated miR-140-5p had much stronger
chondroprotective abilities and the treated joint showed a very low level of
osteochondral degeneration
Vonk et al., 2018 [106] Human bone marrow-derived MSCs Exosomes (40–150 nm)
EVs were added to cells over a period of 48 h
(inflammatory model) or 28 days with repeated
treatment every five days (cartilage
regeneration model)
In vitro:
Inflammatory model–human OA chondrocytes
stimulated with TNF-α; cartilage regeneration
model–human OA chondrocytes cultured in
fibrin matrices
- In inflammatory model, EVs suppressed TNF-α and COX2 expression, as
well as pro-inflammatory interleukins (IL-1α, IL-1β, IL-6, IL-8, IL-17)
- In cartilage regeneration model, EVs improved proteoglycan content and
upregulated the production of collagen type II
Wang et al., 2017 [111] Human ESC-derived MSCs Exosomes (38–169 nm)
Intra-articular injection of 1 × 106 particles in 5 µL
PBS in the bilateral joints, every 3 days for 28 days
after OA induction
In vitro:
Mouse articular chondrocytes treated with IL-1β
In vivo:
DMM mouse model of OA
In vitro:
- Reversed the increased synthesis of collagen type II and ADAMTS5
expression in IL-1β-treated chondrocytes
In vivo:
- Significant chondroprotection and attenuation of OA progression
- Maintained collagen type II content and lower levels of ADAMTS5





Not specified; mostly small EVs (around 100 nm)
In vitro: Cells treated with 1 × 108 or 2 × 108
particles/mL
In vivo: Intra-articular injection of 1 × 108 particles
in a 30 µL volume per joint
In vitro: Human OA chondrocytes treated with
IL-1β
In vivo: MIA rat model of OA and DMM mouse
model of OA
In vitro:
- Reduced catabolic gene expression
- Reduced MMP-1, MMP-3, MMP-13, and ADAMTS5 expression
- Increased collagen type II synthesis
- Reduced expression of pro-inflammatory and cartilage degradation genes
In vivo:
- Reduced cartilage erosion, OA progression, and proteoglycan degradation
- Reduced synovial inflammation and inhibited M1 macrophage infiltration
into the synovium
- Reduced MMP-13 expression
- Maintained adipocyte content of infrapatellar fat pad
- Did not demonstrate subintimal fibrosis and neovascularisation
Wu et al., 2019 [85] MSCs from human intrapatellar fat pad Exosomes (average 121.9 nm)
In vitro:
Cells treated with different concentrations (1, 5, or
10 × 108 particles/mL) in the presence or absence of
IL-1β (10 ng/mL)
In vivo:
Intra-articular injection of 1 × 1010 particles/mL in




DMM mouse model of OA
In vitro:
- Increased chondrocyte viability and cell migration
- Partially reversed IL-1β-induced apoptosis
- Reversed IL-1β-induced changes to ADAMTS5, MMP-13 and collagen
type II expression
In vivo:
- Attenuated cartilage degradation and promoted cartilage maintenance
- Reversed DMM-induced changes to MMP-14, ADAMTS5, and collagen
type II expression
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Xiang et al., 2018 [107] Human bone marrow-derived MSCs MVs (average 200 nm)
In vitro:
Cells were treated with 5–20 µL MVs isolated from
1 × 106 MSCs, for 12 h
In vivo:
Intra-articular injection of 30 µL MVs at three days
after defect creation
In vitro:
Human chondrocytes treated with IL-1β
(10 ng/mL)
In vivo:
Osteochondral defects (4 mm diameter, 5 mm depth)
in the medial femoral condyle of rabbits
In vitro:
- Cells showed EV uptake, which was CD44 dependent
- Increased proliferation potential and decreased apoptosis rate
In vivo:
- At 20, 40, and 60 days, MV-treated group caused gradual defect filling
with hyaline-like tissue rich in collagen type II, reaching the heigh of native
cartilage; PBS-treated group showed no significant regeneration,
with adipose and fibrotic cells progressively filling the defect
Zhang et al., 2018 [113] MSCs derived from a human embryoniccell line Exosomes (average 100 nm)
Intra-articular injection of 100 µg exosomes in





Osteochondral defects (1.5 mm diameter, 1 mm
depth) in the knee joint of rats; analysis at 2, 6,
and 12 weeks
In vitro:
- Cells showed increased migration and proliferation potential proportional
to the dose of exosomes
- Increased ECM synthesis and decreased apoptosis
In vivo:
- Promoted hyaline-like cartilage regeneration
- Increased collagen type II and s-GAG content
- Increased cell proliferation and apoptosis attenuation
- Caused increase in cells presenting PCNA and a more rapid decrease in
CP3 apoptotic cells
- Increased abundance of M2 macrophages in the synovium and cartilage,
and decreased M1 macrophages and inflammatory cytokines
Zhang et al., 2016 [112] MSCs derived from a human embryoniccell line Exosomes (average 100 nm)
Intra-articular injection of 100 µg exosomes in
100 µL PBS once per week for 12 weeks after
OA induction
In vivo:
Osteochondral defects (1.5 mm diameter, 1 mm
depth) in the knee joint of rats; analysis at 6 and
12 weeks
- Attenuated cartilage degeneration
- Caused regeneration of hyaline cartilage, and increased GAG and collagen
type II content
- Caused complete regeneration of subchondral bone
Zhu et al., 2017 [110] Human synovial membrane-derived MSCs,and human iPSC-derived MSCs Exosomes (50–150 nm)
Intra-articular injection of 1 × 1010 particles/mL in




Collagenase-induced mouse model of OA; analysis
at 28 days
In vitro:
- Both exosome groups improved chondrocyte migration and proliferation,
with exosomes from iPSC-derived MSC showing more
dramatic improvements
In vivo:
- Both exosome groups showed significant improvements in reducing OA
pathology compared to controls
- Exosomes from iPSC-derived MSCs showed a greater regenerative
potential, presenting with smooth hyaline-like cartilage, normal collagen
type II localisation and healthy proteoglycan content
RHEUMATOID ARTHRITIS
Study Source of EVs Type of EVs Administration and Dose Model(s) Used Major Findings
Chen et al., 2018 [119] Mouse bone marrow-derived MSCs Exosomes (average 100 nm)
Intradermal injection of 50 µg exosomes in 100 µL
PBS twice per week; exosomes were from MSCs
overexpressing miR-150-5p or the control miR-67
In vitro:





- Exosomes enriched with miR-150-5p substantially inhibited tube
formation in HUVEC-FLS co-culture, as well as migration and invasion of
RA FLSs, indicating that they can suppress angiogenesis
- miR-150-5p from enriched exosomes suppressed the expression of
MMP-14 and VEGF, but miR-67 did not have the same effects
In vivo:
- Exosomes enriched with miR-150-5p induced downregulation of MMP-14
and VEGF in tissue, reduction in the thickness of the hind paw, and lower
clinical scores of arthritis compared to groups treated with miR-67 control
exosomes or PBS
- Substantially improved arthritis severity and successfully
inhibited angiogenesis
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Cosenza et al., 2018 [120] Mouse bone marrow-derived MSCs
EVs separated into exosomes (average 120 nm,
expressing CD81 and CD 9) and MVs (150–600 nm,
expressing Sca-1, CD44 and CD29)
Intravenous injection of 250 ng exosomes or 600 ng
MVs in CIA mouse model at 18 and 24 days after
arthritis induction
In vitro:
Mouse spleen T- and B-lymphocytes
In vivo:
Mouse delayed T hypersensitivity (DTH) model
(injection into footpad at five days after
immunisation; analysis at 24 h after injection), and
CIA mouse model (analysis at 30 days)
In vitro:
- EVs from MSCs primed with IFN-γ showed a dose-dependent effect on
T-lymphocyte suppression, but their immunomodulatory effects were lost
after freeze-thawing
- Primed and un-primed exosomes and MVs suppressed ConA-activated
splenocytes to a similar extent
- MSCs exerted the strongest suppression of CD8+ IFN-γ+ cells, followed
by similar levels by exosomes and MVs
- MSCs, exosomes and MVS all increased the percentage of
CD4+ IL-10+ Tr1 cells
- Exosomes and MVs both increased the percentage of CD4+ CD25+ Treg
cells, while MSCs had no effect
- Isolated CD4+ and CD8+ cells treated with exosomes or MVs did not show
reduced proliferation
In vivo:
- In DTH model, both exosomes and MVs showed anti-inflammatory effects
that were dose-dependent
- In CIA model, exosomes and MVs showed significant protection from
developing arthritis; treatment with exosomes showed 5% rate of
developing arthritis, and this 5% had very low clinical arthritis scores;
treatment with MVs did not exert significant protection from arthritis
symptoms, but reduced the incidence to 20% with low clinical scores
- Exosomes and MVs both showed maintenance of subchondral bone,
with exosomes being more effective than MVs
Headland et al., 2015 [123]
Human RA synovial fluid, and human
neutrophils (stimulated or not stimulated
with TNF-α)
MVs (0.05–1 µm; may contain both exosomes
and MVs)
Intra-articular injection of 3 × 104 particles in 5 µL
PBS in k/BxN-induced model at 3 days after
arthritis induction, or in GPI-induced model at 21
days after arthritis induction
In vitro:
Human chondrocyte micromass, and ex vivo rat
cartilage explant
In vivo:
Inflammatory arthritis rat models induced by
k/BxN (analysis at five days after induction) or GPI
(analysis at 25 days after induction)
In vitro:
- Protected against cartilage degradation by reducing IL-8 and PGE2 release,
ECM degradation, and chondrocyte apoptosis
- EVs from neutrophils showed the ability to migrate through the ECM in
rat cartilage explants, and migration was increased in explants treated with
IL-1β; EVs needed to remain intact to migrate and exert
chondroprotective effects
- Although neutrophil-derived EVs had chondroprotective effects, direct
contact between neutrophils and chondrocytes induced apoptosis
In vivo:
- Neutrophils injected into damaged joints migrated towards zones of
inflammation where they released EVs, which showed the ability to
penetrate cartilage ECM
- Protective effects of neutrophil-derived EVs were thought to be related to
AnxA1 and FPR2/ALX interactions, which increased the production of
TGF-β in chondrocytes
Meng et al., 2020 [121] Human bone marrow-derived MSCs Exosomes (approximately 100 nm) Cells were treated with 20 µg/mL exosomes fromMSCs overexpressing miR-124a
In vitro:
Human RA FLS cell line
- Exosomes enriched with miR-124a showed the ability to enter cells,
providing significant numbers of exosomes and high levels of miR-124a
in cells
- Suppressed RA FLS proliferation, inhibited wound closure healing rate at
24 h, and inhibited migration and invasion
- Exosomes enriched with miR-124a arrested the cell cycle in the G0/G1
phase, compared to control exosomes at the S phase
- Both miR-124a-enriched and control exosomes promoted RA
FLS apoptosis
Zheng et al., 2020 [122] Rat bone marrow-derived MSCs Exosomes (101 ± 14.45 nm)
Injection of 50 µg exosomes in 100 µL PBS twice
per week, starting at three weeks after the second
arthritis induction procedure; exosomes were from
MSCs overexpressing miR-192-5p
In vivo:
CIA rat model, with two inductions 21 days apart
- Exosomes enriched with miR-192-5p showed the ability to migrate from
the bloodstream to synovial tissues, where they significantly increased
miR-192-5p expression and reduced RAC2 expression
- Reduced TRAP activity (usually elevated in CIA model)
- Significantly attenuated the elevated levels of PGE2, IL-1β, and TNF-α
levels in synovial tissues, and levels of NO and iNOS in serum (usually
elevated in CIA model); exosomes enriched with miR-192-5p had greater
effects than control exosomes
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ALZHEIMER’S DISEASE
Study Source of EVs Type of EVs Administration and Dose Model(s) Used Major Findings
Bodart-Santos et al., 2019 [135] Human Wharton’s jelly mesenchymalstem cells
Not specified, contained both exosomes and MVs
(mostly 50–300 nm) Cells were cultured with 6 × 10
8 EV particles
In vitro:
Hippocampal cells were isolated from hippocampi
from 18-day old rat embryos, and conditioned or not
with AβOs for 2 h
- Control cells showed low uptake of EVs, while AβO-treated cells showed
much higher levels of EV uptake
- EV uptake was primarily performed by astrocytes rather than
neuronal cells
- Once catalase in EVs was inactivated, the EVs no longer prevented the
formation of ROS in AβO-treated cells
- EV treatment of AβO-treated cells for 22 h prevented synapse damage
Cui et al., 2019 [127] Mouse bone marrow-derived MSCs Exosomes, tagged with rabies viral glycoprotein(RVG) which targets the CNS
Intravenous injection of tagged and untagged
exosomes at 5 × 1011 particles in 100 µL PBS, once
per month for four months
In vivo:
APP/PS1 transgenic mouse (prone to early onset
of AD)
- Conjugated RVG-exosomes travelled from the bloodstream to the cortex
and hippocampus at much greater numbers than unconjugated exosomes
- Conjugated exosomes greatly reduced the levels of cortex and
hippocampus plaque deposition, soluble Aβ40 and Aβ42, insoluble Aβ40
and Aβ42, and GFAP expression (astrocyte marker) in the brain;
unconjugated exosomes showed smaller effects
- Conjugated exosomes caused improved spatial recognition and memory
retention as shown through MWM test
- Conjugated exosomes substantially downregulated the pro-inflammatory
markers IL-1α, IL-1β and IL-6, and upregulated the anti-inflammatory
markers IL-4, IL-10 and IL-12
de Godoy, 2018 [128] Rat bone marrow-derived MSCs Not specified, contained both exosomes and MVs(mostly 50–300 nm)
Cells were cultured with 8 × 107 EV particles
(corresponds to ~5000 MSCs), dose tripled in
some experiments
In vitro:
Hippocampal neuronal cells treated with AβOs
- Prevented AβO-induced synapse damage in neurons
- EVs that had catalase (an antioxidant) removed lost the ability to protect
against oxidative stress
- Functional ability of EVs was maintained after cryopreservation
Ding et al., 2018 [133] Human umbilical cord-derived MSCs Exosomes (30–150 nm)
In vitro:
Cells were cultured with exosomes at 30 µg/mL
In vivo:
Intravenous injection of 30 µg exosomes in 100 µL
PBS every two weeks for eight weeks
In vitro:




- Cells showed alternative activation into anti-inflammatory M2 microglia,
with decreased levels of pro-inflammatory cytokines (IL1β, TNF-α) and
increased levels of anti-inflammatory cytokines (IL-10, TGF-β)
In vivo:
- Increased memory as shown through MWM test
- Decreased numbers of Aβ plaques in the hippocampus and cortex, and
soluble Aβ40 and Aβ42 in the brain
- Greatly increased the levels of NEP and IDE (Aβ-degrading enzymes)
- Decreased levels of Iba-1 positive (pro-inflammatory M1) microglia,
and increased expression of markers for anti-inflammatory M2 microglia
Elia et al., 2019 [129] Mouse bone marrow-derived MSCs Not specified, contained both exosomes and MVs(mostly 50–300 nm)
Intracerebral injection of 22.4 µg EVs
(1 × 109 particles) in 4 µL PBS
In vivo:
APP/PS1 transgenic mouse, two age groups
(three and five months; earliest signs of cognitive
impairment appear at six months); analysis at 25
days after injection
- Reduced Aβ plaque area and density in the hippocampus and cortex
- Reduced plaque solidarity in the neocortex (site of injection)
- Lower numbers of plaques surrounded by dystrophic neurites
- Introduces the possibility for intervention before clinical manifestation
of AD
Li et al., 2020 [137] Mouse hippocampus NSCs Not specified (50–190 nm) Injection of 200 µg EVs in 10 µL PBS bilaterally intothe lateral ventricles, twice a week for four weeks
In vivo:
APP/PS1 transgenic mouse
- Increased memory as shown through MWM test
- Upregulated the expression of mitochondrial function-related factors and
synaptic proteins
- Significantly reduced the ratio of damaged to total synapses
- Significantly reduced the levels of pro-inflammatory IL-1β, IL-4, IL-10,
p65, and TNF-α, as well as Iba-1 expression compared to vehicle control
- No significant differences in the levels of soluble and insoluble Aβ40 and
Aβ42 between EV-treated and vehicle control groups
Losurdo et al., 2020 [130] Human bone marrow-derived MSCs Not specified, contained both exosomes and MVs(average 200 nm)
In vitro:
Cells were cultured with EVs (4.5 µg/mL) from
MSCs pre-conditioned with TNF-α and IFN-γ
In vivo:
Intranasal spurts of 5 µL EV solution (300 µg/mL)
totalling 100 µL, given twice at 18 h apart
In vitro:
Microglia cultures consisting of hippocampal and
cortical astrocytes, treated with TNF-α and IFN-γ
In vivo:
Female triple-transgenic AD mouse expressing three
mutant human transgenes (PS1M146V, APPSwe,
and tauP301L)
In vitro:
- Reduced expression of pro-inflammatory markers IL-6 and IL-1β,
and increased expression of the anti-inflammatory marker IL-10
- Completely or partly attenuated the negative effects exerted by
pro-inflammatory cytokine treatment
In vivo:
- Reduced Iba-1+ cell density, together with reduction in microglial cell
body size
- Reduced CD68 expression associated with the activated
microglia phenotype
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Ma et al., 2020 [132] Human adipose MSCs EVs (130 ± 28 nm)
In vitro:
Cells were cultured with EVs for 24 h
In vivo:
Intranasal administration of 10 µL EVs at the
protein dose of 1 mg/kg every two days for
two weeks
In vitro:
Primary neurons from embryonic mice, treated with




- RNA sequencing showed neuroprotective effects of EVs, with some
upregulated genes important for synaptic function, and downregulated
genes related to cell death
- Significantly reversed neuronal toxicity induced by Aβ1-42 oligomers or
glutamate; increased cell viability
In vivo:
- Reduced neurologic damage in whole brain areas, and remarkably
increased neurogenesis
- Slightly reduced Aβ deposition and microglia activation
- Rescued memory deficits as shown through NOR and Y-maze tests
Reza-Zaldivar et al., 2019 [136] MSCs (from ATCC) Exosomes (size unspecified) Intra-peritoneal injection of 10 µg exosomes in 2 µLPBS; analysis at 14 and 28 days after injection
In vivo:
C57BL/6 mouse treated with Aβ aggregates, and
AD allowed to develop for 14 days
before intervention
- Improved spatial learning and memory as shown through MWM test
- Increased scores in NOR test
- Stimulated expression of neurogenesis markers in the subventricular zone
- Increased numbers of immunoreactive cells compared to PBS control, but
similar numbers compared to MSC-treated group
Wang et al., 2020 [131] Mouse bone marrow-derived MSCs Exosomes (approximately 110 nm)
Injection of exosomes (50 µg in 80 µL saline)




- Significantly improved spatial learning and memory ability as shown
through MWM test
- Reduced amyloid levels in the cortex and hippocampus, and enhanced the
expression of NeuN
- Reduced Aβ1-40, Aβ1-42, BACE1, and PS1 expression, and promoted
NEP expression in the brain
- Effects were mediated by activating the SphK/S1P signalling pathway
Yang et al., 2020 [134] Human umbilical cord MSCs Exosomes (50–150 nm)
In vitro:
Cells were cultured with 2 µg exosomes for 24 h;
exosomes were isolated from MSCs cultured on 2D
graphene film or 3D graphene scaffold
In vivo:
Exosomes were delivered by infusion into the right
hippocampus, at 0.25 µL/h (2 mg protein/mL) for
14 days
In vitro:
AD pathology cell model, comprising SH-SY5Y cells
transfected with amyloid precursor protein (APP)





- 3D-exosomes had greater effect in upregulating α-secretase and
downregulating β-secretase to reduce levels of secreted and
intracellular Aβ
In vivo:
- 3D exosomes were more effective at improving spatial learning and
memory function, as shown through MWM test
- Exosomes were mainly concentrated at the site of delivery but also
distributed throughout the brain parenchyma; 3D exosomes were more
effective at decreasing Aβ deposition by eliminating production and
facilitating clearance of Aβ
- Exosomes reduced neuroinflammation by attenuating microglial
activation, and markedly reduced oxidative stress; 3D exosomes produced
more pronounced effects
CARDIOVASCULAR DISEASE
Study Source of EVs Type of EVs Administration and Dose Model(s) Used Major Findings
Chen et al., 2020 [147] Rat bone marrow MSCs Exosomes (60–100 nm), enriched with miR-125b orcontrol miR-67
Exosomes (50 µg) were injected into the ligation
zone contiguous to the left anterior free wall after
left ventricle exposure
In vivo:
Rat I/R model, in which the LAD was ligated for 30
min followed by reperfusion for 2 h
- Increased cell viability and inhibited inflammation, oxidative stress
and apoptosis
- Reduced infarct size and improved cardiac function, with increased LVEF,
LVFS and LVSP
- Upregulated miR-125b and anti-apoptotic Bcl-2, and downregulated
pro-apoptotic factors Bax and caspase-3
- Decreased the levels of inflammatory factors IL-1β, IL-6 and TNF-α
- Downregulated SIRT7 gene and protein expression
Firoozi et al., 2020 [151] Human bone marrow MSCs EVs (average 100 nm)
EVs (80 µg) were injected in a 100 µL volume,
directly or encapsulated in an SAP hydrogel, into
four sites of the infarct border zone after ligation
In vitro:
Neonatal mouse cardiomyocytes treated with H2O2
In vivo:
LAD coronary artery ligation rat model of MI
In vitro:
- Protected cardiomyocytes from damage due to H2O2-induced
oxidative stress
In vivo:
- Improved LVEF and LVFS, promoted cardiac morphological status and
preserved function
- Reduced fibrosis area, apoptosis and inflammation; reduced expression of
pro-inflammatory CD68+ cells
- Promoted angiogenesis in infarcted myocardium, with increased numbers
of α-SMA+ structures
- Both encapsulated and free EVs improved cardiac function, likely by
reducing macrophage infiltration and increasing angiogenesis
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Han et al., 2019 [152] Human umbilical cord MSCs Exosomes (size unspecified)
Exosomes (20 µg) were injected in a 20 µL volume,
directly or encapsulated in a peptide hydrogel, into
two different sites next to the infarcted border region
after ligation
In vitro:
Rat H9C2 cardiomyoblasts treated with H2O2
In vivo:
LAD coronary artery ligation rat model of MI
In vitro:
- Exosomes protected cell damage from H2O2-induced oxidative stress and
improved cell viability
In vivo:
- Improved cardiac function with increased LVEF and LVFS
- Reduced infarct size and length, fibrosis area, and apoptosis
- Promoted angiogenesis in infarcted myocardium
- Hydrogel facilitated prolonged and stable release of exosomes in the area
of ischaemic myocardium
- Decreased expression of TGF-β1 (pro-fibrosis), CD68 (indicative of
inflammatory cell infiltration), and TNF-α (pro-inflammatory)
- Increased diameter of CD31+ blood vessels and reduced number of
apoptotic cells
- Growth hormone releasing peptide-6 (GHRP6) was released following
hydrogel degradation, activating pro-survival PI3K/Akt1 and TGF-β1
pathways and inhibiting the NF-kB pathway
Huang et al., 2019 [154] Rat bone marrow MSCs Exosomes (average 100 nm)
Exosomes (10 µg in 100 µL PBS) were injected at
3 sites around the infarct border 30 min after ligation,
with or without intravenous delivery of
atorvastatin-pretreated MSCs through the tail vein at
day 1, 3, or 7 after MI
In vivo:
LAD coronary artery ligation rat model of MI
- Exosome and MSC combinatorial treatment caused improved cardiac
function with increased LVES and LVFS, reduced infarct size and collagen
area, and increased neovascularisation (microvascular density in both
arteriolar and capillary vessels) compared to exosomes or MSCs alone
- Intramyocardial injection of exosomes 30 min after AMI combined with
MSC transplantation at 3 days after AMI achieved the highest improvement
in heart function
- Combinatorial therapy reduced inflammation, with increased expression
of the pro-survival protein Bcl-2, reduced number of apoptotic cells,
and decreased levels of inflammatory cytokines IL-6 and TNF-α
Liu et al., 2017 [143] Rat bone marrow-derived MSCs Exosomes (50–100 nm)
In vitro:
Cells were cultured with exosomes (10 µg/mL) for
6, 12, and 24 h
In vivo:
Exosomes (5 µg in 10 µL PBS) were injected into
the anterior and lateral part of the visibly injured
region 5 min before reperfusion
In vitro:
Rat H9C2 cardiomyoblasts treated with H2O2
In vivo:
Rat I/R model, in which the LAD was ligated for 30
min followed by reperfusion for 2 h
In vitro:
- Enhanced cell viability, and reduced cell apoptosis and ROS production
after H2O2 stimulation
- Increased cell autophagy, which was regulated by AMPK/mTOR and
Akt/mTOR signalling; upregulated p-AMPK/AMPK ratio and
downregulated p-Akt/Akt and p-mTOR/mTOR ratio
In vivo:
- Reduced cardiomyocyte apoptosis and infarct size
- Improved cardiac function with increased LVEF and LVFS
Milano et al., 2020 [150]
Human cardiac-resident
mesenchymal progenitor cells (obtained from
right cardiac appendage tissue)
Exosomes (mostly < 150 nm)
In vitro:
Cells were pre-treated with exosomes for 1 h before
inducing oxidative stress
In vivo:
Exosomes (3 × 1010 particles in 100 µL) were
injected into the tail vein at 5, 11, and 19 days after
study commencement
In vitro:
Neonatal rat ventricular myocytes treated with
doxorubicin (Dox) and trastuzumab (Trz) to induce
oxidative stress
In vivo:
Rats injected with six doses of Dox (days 1–11) and
six doses of Trz (days 19–28)
In vitro:
- Prevented increase in ROS induced by Dox/Trz
- Enriched in miR-146a-5p compared to exosomes from human dermal
fibroblasts; suppressed expression of Traf6, Smad4, Irak1, Nox4, and Mpo
(known target genes of miR-146a-5p) in Dox-treated cells, which might
provide protection against Dox-induced cell death
In vivo:
- Prevented Dox/Trz effects on left ventricular dysfunction, myocardial
fibrosis, CD68+ macrophage infiltration, and iNOS expression
Shao et al., 2017 [141] Rat bone marrow-derived MSCs Exosomes (size unspecified)
In vitro:
Cells were cultured with exosomes for up to 48 h
In vivo:
Exosomes (20 µg in 20 µL PBS) were injected at two
different sites beside the infarct border region
after ligation
In vitro:
Rat H9C2 cardiomyoblasts or BJ fibroblasts treated
with TGF-β
In vivo:
LAD coronary artery ligation rat model of MI
In vitro:
- Enhanced proliferation capacity and inhibited apoptosis in H9C2 cells
- Reduced TGF-β-induced α-SMA expression and inhibited fibroblast
transformation
- Compared to MSCs, exosomes had lower expression of miR-21 and miR-15
- Upregulated PI3k-Akt and mTOR pathways
In vivo:
- Decreased infiltration of CD68+ inflammatory cells,
and inhibited apoptosis
- Improved cardiac function with increased LVEF and LVFS
Shi et al., 2019 [138] Human umbilical cord MSCs Exosomes (mostly 100 nm) Exosomes (400 µg) were given by intramyocardialadministration during surgery
In vitro:
Rat neonatal cardiomyocytes, and cardiac fibroblasts
treated with LPS
In vivo:
LAD coronary artery ligation rat model of MI
In vitro:
- Increased myofibroblast density and improved collagen contraction
- Promoted fibroblast-to-myofibroblast differentiation in inflammatory
environments
- Reduced cardiomyocyte apoptosis
- Decreased fibroblast migration, but no effect on fibroblast proliferation
- Decreased expression of IL-1β and TNF-α, and increased expression
of TGF-β
In vivo:
- Suppressed inflammatory response and improved cardioprotective effects
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Sun et al., 2018 [144] Mouse bone marrow MSCs Exosomes (average 35 nm)
Exosomes (300 µg in 200 µL PBS) were injected
intravenously through tail vein seven days after
disease induction
In vivo:
Doxorubicin-induced mouse model of dilated
cardiomyopathy
- Improved cardiac function with increased LVEF and LVFS
- Attenuated cardiac dilation and reduced cardiomyocytes apoptosis
- Decreased expression of pro-apoptotic protein Bax, and increased
expression of pro-survival protein Bcl-2
- Decreased levels of inflammatory cytokines IL-1, IL-6 and TNF-α in serum
- Reduced pro-inflammatory ILY6Chigh and M1-like F4/80+ CD11c+
macrophages, and elevated anti-inflammatory LY6Clow and M2-like
F4/80+ CD206+ macrophages
- Regulated macrophage polarisation through activation of the
JAK2-STAT6 pathway
Wang et al., 2018 [153] Mouse bone marrow MSCs Exosomes (30–150 nm), engineered throughlentiviral packaging technology
Exosomes (4 × 109 particles or 50 µg) in 100 µL
were injected intravenously through the tail vein
after ligation
In vitro:
Hypoxia-induced rat H9C2 cardiomyoblasts
In vivo:
LAD coronary artery ligation mouse model of MI
In vitro:
- IMTP-exosomes produced by transfected MSCs were internalised to a
greater extent by hypoxia-injured H9C2 cells than blank exosomes
In vivo:
- IMTP-exosomes allowed prolonged delivery in the region of
ischaemic myocardium
- Decreased inflammation and apoptosis, with reduced expression of
pro-inflammatory factors (IL-6, TNF-α, IL-1β)
- Reduced M1 macrophages (TNF-α+, CD68+) and increased M2
macrophages (CD206+)
- Improved revascularisation and cardiac function, with increased capillary
density and number of arterioles
Xu et al., 2020 [29] Human MSCs from bone marrow, adiposetissue and umbilical cord Exosomes (mostly < 100 nm) for all MSC types
Injection of exosomes or MSCs (1.5 × 106 cells) in
150 µL PBS at the margin area of MI 30 min
after ligation
In vivo:
LAD coronary artery ligation rat model of MI
- Exosomes promoted angiogenesis, reduced infarct size, inhibited
cardiomyocyte apoptosis, and improved microvascular density
- Decreased LVESD and LVEDD, increased LVEF and LVFS, and improved
cardiac function
- Increased the levels of angiogenesis factors VEGF, bFGF, and HGF
- Decreased adverse cardiac remodelling
Xu et al., 2019 [149] Rat bone marrow-derived MSCs Exosomes (mostly 100 nm)
Exosomes (from 1 × 106 LPS-primed or non-primed
MSCs) were injected at four sites into myocardium




LAD coronary artery ligation mouse model of MI
In vitro:
- Exosomes decreased the expression of pro-inflammatory TNF-α, IL-6 and
IL-1β, and increased the expression of anti-inflammatory IL-10;
LPS-primed exosomes showed greater downregulation of
pro-inflammatory cytokines
- LPS-primed exosomes significantly reduced pro-inflammatory M1
macrophage protein markers (CD11b, iNOS) and elevated
anti-inflammatory M2 macrophage protein markers (CD206, ArgI)
- LPS-primed exosomes regulated macrophage polarisation by suppressing
NF-κB signalling, and activating AKT1/AKT2 signalling
In vivo:
- Attenuated post-infarction inflammation by mediating macrophage
polarisation, reduced cardiomyocyte apoptosis, and improved cardiac
function; LPS-primed exosomes had greater effects
Zhao et al., 2019 [145] Mouse bone marrow MSCs Exosomes (50–150 nm)
Exosomes (50 µg in 25 µL PBS) were injected at
three different points of the peri-infarct myocardial
region after reperfusion
In vivo:
Mouse I/R model, where the LAD was ligated for 45
min followed by reperfusion; for macrophage
depletion studies, mice were intravenously injected
with 150µL (5 mg/mL) clodronate liposomes
- Improved cardiac function; reduced infarct size, fibrosis, hypertrophy of
cardiomyocytes, and myocardial injury
- Reduced infiltration of inflammatory cells and inflammation of heart tissue
- Decreased pro-inflammatory cytokines (IL-6) and increased
anti-inflammatory cytokines (IL-10) in serum and heart tissues
- Reduced M1 macrophages and M1 gene expression markers (iNOS, IL-1β,
IL-6, TNF-α), and increased M2 macrophages and M2 gene expression
markers (Arg1, IL-10, CD206, TGF-β)
- Downregulated TLR4, and upregulated PI3k/Akt signalling pathway
through miR-182 in association with immunomodulation effects
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Zhu et al., 2019 [146] Human umbilical cord MSCs Exosomes (size unspecified) Exosomes (100 µg/injection) were injected in thetail vein three times per week for six weeks
In vitro:
Rat H9C2 cardiomyoblasts treated with treated
with H2O2
In vivo:
Mouse model of aging and cardiac dysfunction
induced by D-galactose
In vitro:
- Promoted cell proliferation and prevented senescence
- Inhibited the activity of the cell senescence mediator NF-κB and the
expression of its subunit p-p65
- Exosomes prevented cell senescence through the lncRNA MALAT1, by
inhibiting the NF-κB/TNF-α pathway
In vivo:
- Improved cardiac function with increased LVEF and LVFS
- Attenuated the effects of D-galactose and preserved telomere length
- Increased the anti-aging marker TERT and decreased the aging marker p21
- Reduced the expression of pro-inflammatory TNF-α
- Protective effects of exosomes were blocked by silencing the
lncRNA MALAT1
PREECLAMPSIA
Study Source of EVs Type of EVs Administration and Dose Model(s) Used Major Findings
Liu et al., 2020 [161] Human umbilical cord MSCs Exosomes (30–120 nm) Abdominal injection of exosomes (160 µg/mL) at0.5 mL/day from day 14 to 19 of gestation
In vitro:
HTR-8/SVneo human trophoblast cell line
In vivo:
Rat preeclampsia model induced by L-NAME
In vitro:
- Hindered cell apoptosis by inhibiting c-caspase-3 activity
- Increased miR-139-5p expression in trophoblasts, showing pro-angiogenic
and anti-inflammatory function
- Inhibited PTEN expression and promoted ERK/MMP-2 pathway
activation through miR-139-5p
In vivo:
- Decreased blood pressure and proteinuria
- Restored miR-139-3p expression in placental tissue, and reduced
expression of PTEN and MMP-2
Wang et al., 2020 [160] Human umbilical cord MSCs Exosomes (average 130 nm) Cells were treated with exosomes for three days;exosomes were from MSCs overexpressing miR-133b
In vitro:
HPT-8 and HTR8-S/Vneo human trophoblast
cell lines
- Promoted trophoblast proliferation, migration, invasion ability, and cell
cycle progression, and inhibited cell apoptosis; effects were more
pronounced in exosomes enriched with miR-133b overexpression
- In placental tissue of preeclampsia patients, miR-133b is downregulated
and SGK1 is up-regulated
- Exosomal miR-133b may act by reducing SGK1 expression
Xiong et al., 2018 [162] Human umbilical cord MSCs Exosomes (30–100 nm)
Abdominal injection of low (120 µg/mL), medium
(140 µg/mL), or high (160 µg/mL) dose exosomes
at 0.5 mL/day for 6 days, starting on day 14
of gestation
In vivo:
Rat preeclampsia model induced by L-NAME
- Decreased blood pressure and proteinuria
- Dose-dependent increase in foetus number and quality, as well as
microvascular density
- Decreased expression of anti-angiogenic sFlt1 and increased expression of
pro-angiogenic VEGF in placental tissue, with the high exosome dose
showing the most prominent effects
Zheng et al., 2020 [159] Decidual MSCs from human placenta Not specified, mostly small EVs (224.2 ± 4.2 nm) Cells were treated with EVs (100 µg/mL, pooledfrom 6 patient samples) in 100 µL culture medium
In vitro:
HUVECs treated with LPS or human
preeclampsia serum
- Increased cell attachment and proliferation, and reduced production of
pro-inflammatory IL-6 in both HUVEC models
- No significant effect on lipid peroxidation in LPS-treated HUVECs, but
significantly reduced lipid peroxidation in preeclampsia serum-treated
HUVECs
AβO: amyloid-β oligomer; AD: Alzheimer’s disease; ATCC: American Type Culture Collection; bFGF: basic fibroblast growth factor; CIA: collagen-induced arthritis; CNS: central nervous system; DMM: destabil-
isation of the medial meniscus; ECM: extracellular matrix; ESC: embryonic stem cell; EV: extracellular vesicle; FLS: fibroblast-like synoviocytes; GAG: glycosaminoglycan; GPI: glucose-6-phosphate isomerase;
HGF: hepatocyte growth factor; HUVEC: human umbilical vein endothelial cell; I/R: ischaemia-reperfusion; IDE: insulin-degrading enzyme; IFN: interferon; IL: interleukin; IMTP: ischemic myocardium-targeting
peptide; iNOS: inducible nitric oxide synthase; iPSC: induced pluripotent stem cell; LAD: left anterior descending; lncRNA: long noncoding RNA; LPS: lipopolysaccharide; LVEF: left ventricular ejection
fraction; LVFS: left ventricular fractional shortening; LVSP: left ventricular systolic pressure; LVESD: left ventricular end systolic diameter; LVEDD: left ventricular end diastolic diameter; MI: myocardial
infarction; MIA: monosodium iodoacetate; MMP: matrix metalloproteinase; MSC: mesenchymal stem cell; MV: microvesicle; MWM: Morris water maze; NEP: neprilysin; NO: nitric oxide; NOR: Novel Object
Recognition; NSC: neural stem cell; OA: osteoarthritis; PGE2: prostaglandin E2; PBS: phosphate buffered saline; PCNA: proliferating cell nuclear antigen; RA: rheumatoid arthritis; ROS: reactive oxygen species;
s-GAG: sulfated glycosaminoglycan; SAP: self-assembling peptide; TGF: transforming growth factor; TNF: tumour necrosis factor; TRAP: tartrate-resistant acid phosphatase; VEGF: vascular endothelial
growth factor.
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MSCs have gained growing attention as a potential therapeutic strategy to alleviate in-
flammation, oxidative stress, and restricted angiogenesis in preeclampsia [156]. MSC treat-
ment has been shown to cause deactivation of both innate and adaptive inflammatory
immune cells including monocytes, macrophages, dendritic cells (DCs), CD4+ and CD8+
cells, natural killer (NK) cells, and B-cells, as well as activation of a regulatory sub-set of im-
mune cells to resolve inflammation in preeclampsia [156]. MSC-derived EVs have recently
been explored as an alternative, safer and more effective option to whole cell-based therapy
for the treatment of preeclampsia. A number of studies have investigated the functional
role of the miRNA cargo of MSC-derived EVs, which can metabolically induce changes in
macrophage phenotype from a glycolysis-conducted M1 pro-inflammatory phenotype to
an oxidative phosphorylation-dependent M2 anti-inflammatory phenotype [156].
From the four studies shown in Table 1 on testing MSC-derived EVs in models of
preeclampsia, two were in vitro studies performed using HUVECs [159] or trophoblasts [160]
as cell models, while the other two were in vivo studies performed in rat models of
preeclampsia [161,162]. EVs derived from human decidua MSCs were found to enhance
HUVEC proliferation by reducing inflammation and oxidative stress [159]. The addition
of EVs to LPS-treated HUVECs also caused a significant reduction in pro-inflammatory
IL-6 cytokine concentration. On the other hand, exosomes from human umbilical cord
MSCs were found to promote cell proliferation, migration and cell cycle entry, as well as
inhibit apoptosis in human trophoblast cell lines [160]. These effects were increased when
exosomes were derived from the same MSCs transfected with miR-133b. The exosomal miR-
133b was shown to exert its effects on trophoblasts by regulating glucocorticoid-regulated
kinase 1 (SGK1).
The two studies that performed in vivo testing to investigate the effects of MSC-
derived EVs in rat models of preeclampsia both used human umbilical cord MSCs as
the cell source for producing EVs. One study using exosomes from the MSCs showed
that these significantly lowered blood pressure and proteinuria in the animal model,
both key features of preeclampsia [161]. From in vitro experiments performed in the
same study, it was noted that the exosomes could promote trophoblast cell migration,
invasion and proliferation while reducing apoptosis, possibly by transferring miR-139-
5p to the trophoblasts and thereby regulating the ERK/MMP-2 pathway. In the other
study, the exosomes were administered at low, medium or high doses to the animals [162].
Their effects included lowering blood pressure and proteinuria, as well as increasing the
number and quality of foetuses, quality of the placenta, microvascular density of the
placenta, and VEGF expression while decreasing cell apoptosis and the expression of the
anti-angiogenic factor sFlt1. It was interesting to note that the effects of exosomes were
exerted in a dose-dependent manner.
8. Limitations and Future Perspectives of Using Extracellular Vesicles from
Mesenchymal Stem Cells for the Treatment of Inflammation-Related Conditions
As demonstrated by the studies discussed in this review, the use of MSC-derived
EVs has potential to provide substantial therapeutic benefits in a range of inflammation-
related conditions, including osteoarthritis, rheumatoid arthritis, Alzheimer’s disease,
cardiovascular disease, and preeclampsia. To date, a small number of studies have been
published on applying MSC-derived EVs for each of these conditions in experiments
involving in vitro and small animal models of disease. The field of using MSC-derived EVs
as therapeutics is still in its infancy, but holds significant promise as a viable option in the
management and treatment of inflammatory conditions. Compared to injecting live cells,
MSC-derived EVs offer a prominent advantage in the ability to be used as off-the-shelf
therapeutics, since they can be preserved in cold storage for long periods of time without
loss of biological activity upon thawing, for example, at −20 ◦C for six months [163] or at
−80 ◦C for up to two years [164]. The isolation and purification of EVs from the conditioned
medium that has been used to culture MSCs is expected to be conducted under sterile
conditions, removing the need to perform additional sterilisation prior to EV application,
unlike for locally administered pharmacological agents. Although comprehensive analyses
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are still emerging in the field, preclinical studies have demonstrated that EVs have minimal
toxicity and immunogenicity, even when applied xenogenetically as a large dose at high
frequency [89]. There is a potential safety concern with intravascular injection of large
quantities of EVs, particularly MVs that are shed from the cell membrane, if they express
the same levels of prothrombotic tissue factor (TF/CD142) and collagen type-1 (COL-1) as
the parent MSCs, which may trigger coagulation pathways and lead to blood clots [165].
This is an area that warrants further investigation, although it is less concerning in the
local delivery of MSC-derived EVs to specific tissues, which is the typical method of
administration for regenerative medicine applications. Although MSC-derived EVs show
promising characteristics and preclinical evidence, there remain a number of considerable
questions to answer and limitations to address before the application of these therapeutic
EVs can be translated to a clinical setting.
The exact mechanisms underlying the therapeutic effects of EVs when applied to
different diseases remain incompletely understood in current studies, posing an area where
significantly more work is needed. In particular, the optimal tissue source of MSCs for
generating EVs has been rarely explored. A wide variability in therapeutic efficacy has
been seen across the many MSC sources used in different studies, including bone marrow,
adipose tissue, synovial membrane, induced pluripotent stem cells (iPSCs), and embry-
onic stem cells (ESCs). Direct comparison between studies is difficult due to significant
variations in the culture media and conditions used to generate EVs, isolation methods,
experimental set-up, and EV dosage. Only one study so far has directly compared two
different MSC sources, which showed that EVs derived from iPSCs had superior therapeu-
tic efficacy for the treatment of OA compared to those derived from synovial membrane
MSCs [110]. In addition, few studies have investigated the influence of environmental
conditions and stresses on the molecular cargo and effectiveness of EVs generated by
stem cells [34,166]. These observations raise multiple important questions: (i) which MSC
source possesses the greatest therapeutic potential for a given condition, (ii) which factors
are critical in determining the therapeutic potential of EVs, and (iii) how to optimise the
therapeutic potential of EVs for a chosen MSC source. The posing of these open questions
is further supported by interesting observations from a study showing that EVs from
adipose-derived MSCs cultured in hypoxic conditions exerted a greater regenerative effect
than those cultured in normoxic conditions [82], as well as others demonstrating that the
therapeutic potential of MSC-derived EVs could be improved through enrichment with
specific miRNAs [83–85,119,121,145,148]. In addition to the cell source, another aspect of
EV-based therapy that has not been sufficiently explored is the dosage and frequency of
treatment. Studies which compared variable dose levels of EVs all tend to demonstrate
the best therapeutic outcomes in the highest dose group, creating difficulties in finding
an ‘optimal’ level of EV administration. There is also a wide variation in treatment fre-
quency among the studies included in this review. Further investigations are needed to
elucidate the most effective treatment method for a given disease that takes into consid-
eration the source of MSCs, dose of EVs and frequency of administration, among other
important factors.
The currently available evidence on the therapeutic applications of MSC-derived
EVs in inflammatory conditions are limited to in vitro and small animal studies exploring
the short-term outcomes of EV treatment. There is a critical need for future studies to
investigate the long-term effects. A question remains about whether the regenerative
outcomes and disease attenuation induced by EVs are permanent or temporary. It is
possible that the short-term positive outcomes of EV treatment observed in current studies
are a result of temporarily altered gene expression, and that given sufficient time the
diseased phenotype may return. Addressing this question will enable researchers to
determine if EV treatment will require ongoing administration, and if so, the frequency
that is required to produce a sustained therapeutic effect. Furthermore, it is crucial that
research on EVs as therapeutics is translated to large animal studies, using models such as
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sheep or pigs that may more closely mirror disease progression and treatment response
in humans.
For EVs to become a widely accepted and applied treatment option, a number of
technical limitations pertaining to the general field of EV research needs to be addressed.
Currently, there is no consensus on the optimal methods for EV generation, isolation,
purification and characterisation. To upscale the technology surrounding the use of EVs
as therapeutics, standardisation of these processes is essential [167,168]. EV isolation is
currently achieved through techniques such as centrifugation, immunoaffinity isolation,
polymeric precipitation, size exclusion, and microfluidic devices [47]. Unfortunately, all of
these methods carry certain limitations which reduce the ability to upscale the EV produc-
tion, such as insufficient exclusion capacity resulting in contamination, alteration of EV
structure resulting in a loss of function, and poor isolation capacity resulting in incom-
plete EV fraction isolation and low yield [169]. Another significant challenge lies in the
generation of a sufficient quantity of EVs for practical applications, such as for preclinical
animal models or clinical trials. The current yield of EVs from MSCs in conventional
culture conditions is extremely low, with 1 L of culture medium conditioned with a total
of approximately 60 million MSCs only producing 1–2 mg (protein content) of EVs [170].
With single injections in mice of up to 500 µg EVs used in some studies [104] and many
others conducting weekly injections, it remains a considerable hurdle to upscale these EV
quantities to clinically viable treatment options for humans.
One method that has been explored in the hope of increasing the therapeutic efficacy of
EVs is to load them within a hydrogel for delivery. When delivered in an aqueous solution
(typically saline), EVs are either rapidly absorbed by the tissue at the site of injection or
dissipate to other areas, thereby reducing their effectiveness. The rationale for developing
EV-loaded hydrogel delivery systems is to enable the sustained release of EVs over an
extended period of time. The feasibility of this approach has been reported in a number of
studies, where MSC-derived EVs exhibited increased therapeutic potential to treat chronic
liver failure in a rat model [171] or renal I/R injury in a mouse model [172], when delivered
in vivo within a polymerised hydrogel compared to EVs delivered in an aqueous medium.
The characterisation and quantification of EVs is another area lacking consensus in the
field [167,168]. EV quantification is commonly performed through dynamic light scattering
or nanoparticle tracking analysis, the characterisation of surface markers through protein
analysis by flow cytometry or western blotting, and morphological analysis through elec-
tron microscopy [173]. Nevertheless, there remains significant variation among studies
regarding the types of methods selected for EV characterisation. In addition, the nomencla-
ture for the classification of EVs is currently not consistently defined across the literature,
with different studies implementing varying size ranges and protein markers for distin-
guishing different EV subpopulations such as exosomes and MVs. The importance of
having a standardised set of methods and definitions cannot be overstated, as it is a re-
quirement for clinical application that EVs can be produced in a consistent and accurate
manner to ensure that maximum therapeutic potential along with safety outcomes are
consistently achieved.
The current research strongly suggests that MSC-derived EVs have potential to provide
significant anti-inflammatory and regenerative effects on damaged or diseased tissues in
inflammation-related conditions, particularly when locally administered in large doses.
While the landscape for using MSC-derived EVs in the future as a new generation of
therapeutics appears promising, there is a critical need for enhancing the efficacy and
robustness of EVs, and standardising the methods of EV production and isolation.
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bFGF basic fibroblast growth factor
CIA collagen-induced arthritis
CNS central nervous system
DMM destabilisation of the medial meniscus
ECM extracellular matrix





HGF hepatocyte growth factor





IMTP ischemic myocardium-targeting peptide
iNOS inducible nitric oxide synthase
iPSC induced pluripotent stem cell
LAD left anterior descending
lncRNA long noncoding RNA
LPS lipopolysaccharide
LVEF left ventricular ejection fraction
LVFS left ventricular fractional shortening
LVSP left ventricular systolic pressure
LVESD left ventricular end systolic diameter




MSC mesenchymal stromal cell
MV microvesicle
MWM Morris water maze
NEP neprilysin
NO nitric oxide
NOR Novel Object Recognition
NSC neural stem cell
OA osteoarthritis
PGE2 prostaglandin E2
PBS phosphate buffered saline
PCNA proliferating cell nuclear antigen
RA rheumatoid arthritis
ROS reactive oxygen species
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s-GAG sulfated glycosaminoglycan
SAP self-assembling peptide
TGF transforming growth factor
TNF tumour necrosis factor
TRAP tartrate-resistant acid phosphatase
VEGF vascular endothelial growth factor
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